<SEC-DOCUMENT>0001104659-21-024824.txt : 20210217
<SEC-HEADER>0001104659-21-024824.hdr.sgml : 20210217
<ACCEPTANCE-DATETIME>20210217161309
ACCESSION NUMBER:		0001104659-21-024824
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20210212
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210217
DATE AS OF CHANGE:		20210217

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Corvus Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001626971
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				464670809
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37719
		FILM NUMBER:		21644876

	BUSINESS ADDRESS:	
		STREET 1:		863 MITTEN ROAD
		STREET 2:		SUITE 102
		CITY:			BURLINGAME
		STATE:			CA
		ZIP:			94010
		BUSINESS PHONE:		(650) 900-4520

	MAIL ADDRESS:	
		STREET 1:		863 MITTEN ROAD
		STREET 2:		SUITE 102
		CITY:			BURLINGAME
		STATE:			CA
		ZIP:			94010
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm216892d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:crvs="http://corvuspharma.com/20210212">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_034_crvs_corvuspharma.com_20210212 -->
<!-- Field: Set; Name: xdx; ID: xdx_047_20210212_20210212 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0001626971 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
  <ix:hidden>
    <ix:nonNumeric contextRef="From2021-02-12to2021-02-12" name="dei:EntityCentralIndexKey">0001626971</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2021-02-12to2021-02-12" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    </ix:hidden>
  <ix:references>
    <link:schemaRef xlink:href="crvs-20210212.xsd" xlink:type="simple" />
    </ix:references>
  <ix:resources>
    <xbrli:context id="From2021-02-12to2021-02-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001626971</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-12</xbrli:startDate>
        <xbrli:endDate>2021-02-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    </ix:resources>
  </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="text-align: center; font-size: 14pt; margin-top: 0pt; margin-bottom: 0pt"><b>UNITED STATES</b></p>

<p style="text-align: center; font-size: 14pt; margin-top: 0pt; margin-bottom: 0pt"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="text-align: center; font-size: 14pt; margin-top: 0pt; margin-bottom: 0pt"><b>Washington, D.C. 20549</b></p>

<p style="text-align: center; font-size: 14pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p>

<p style="text-align: center; font-size: 14pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="text-align: center; font-size: 14pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p> <p style="text-transform: uppercase; text-align: center; font-size: 14pt; margin-top: 0pt; margin-bottom: 0pt"><b>Form <span id="xdx_909_edei--DocumentType_c20210212__20210212_zluEpuvtw1ic"><ix:nonNumeric contextRef="From2021-02-12to2021-02-12" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>



<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><b>CURRENT REPORT</b></p>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><b>Pursuant to Section 13 or 15(d) of the</b></p>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><b>Securities Exchange Act of 1934</b></p>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><b>Date of Report (Date of earliest event reported): <span id="xdx_90D_edei--DocumentPeriodEndDate_c20210212__20210212_zzrBh2ZfWCjc"><ix:nonNumeric contextRef="From2021-02-12to2021-02-12" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">February 12, 2021</ix:nonNumeric></span> &#160;</b></p>



<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 24pt"><b><span id="xdx_903_edei--EntityRegistrantName_c20210212__20210212_z8xtorC7EVq4"><ix:nonNumeric contextRef="From2021-02-12to2021-02-12" name="dei:EntityRegistrantName">CORVUS PHARMACEUTICALS, INC.</ix:nonNumeric></span></b></span></p>

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 14pt"><b></b></span><b><span style="font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></b></p>

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b></b></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>



<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="text-align: center; width: 33%"><span style="font-size: 10pt"><b><span id="xdx_908_edei--EntityIncorporationStateCountryCode_c20210212__20210212_z0XSob28hFpb"><ix:nonNumeric contextRef="From2021-02-12to2021-02-12" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center; width: 34%"><span style="font-size: 10pt"><b><span id="xdx_908_edei--EntityFileNumber_c20210212__20210212_z2QCzvm2kx"><ix:nonNumeric contextRef="From2021-02-12to2021-02-12" name="dei:EntityFileNumber">001-37719</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center; width: 33%"><span style="font-size: 10pt"><b><span id="xdx_90A_edei--EntityTaxIdentificationNumber_c20210212__20210212_zhOXVLuqceul"><ix:nonNumeric contextRef="From2021-02-12to2021-02-12" name="dei:EntityTaxIdentificationNumber">46-4670809</ix:nonNumeric></span></b></span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt"><b>(State or other jurisdiction</b></span></p>
                                   <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt"><b>of incorporation)</b></span></p></td>
    <td style="text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt"><b>(Commission</b></span></p>
                                   <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt"><b>File Number)</b></span></p></td>
    <td style="text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt"><b>(IRS Employer</b></span></p>
                                   <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt"><b>Identification Number)</b></span></p></td></tr>
</table>
<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table border="0" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center; width: 100%"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt"><b><span id="xdx_900_edei--EntityAddressAddressLine1_c20210212__20210212_ziykV1v1y81e"><ix:nonNumeric contextRef="From2021-02-12to2021-02-12" name="dei:EntityAddressAddressLine1">863 Mitten Road</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressAddressLine2_c20210212__20210212_zUSJWVrNm0Vh"><ix:nonNumeric contextRef="From2021-02-12to2021-02-12" name="dei:EntityAddressAddressLine2">Suite 102</ix:nonNumeric></span></b></span></p>
                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt"><b><span id="xdx_902_edei--EntityAddressCityOrTown_c20210212__20210212_z2JOY9f9l3Oe"><ix:nonNumeric contextRef="From2021-02-12to2021-02-12" name="dei:EntityAddressCityOrTown">Burlingame</ix:nonNumeric></span>, <span id="xdx_904_edei--EntityAddressStateOrProvince_c20210212__20210212_zkstTPcSnUKd"><ix:nonNumeric contextRef="From2021-02-12to2021-02-12" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric></span> <span id="xdx_908_edei--EntityAddressPostalZipCode_c20210212__20210212_zTuOTxLIy9r1"><ix:nonNumeric contextRef="From2021-02-12to2021-02-12" name="dei:EntityAddressPostalZipCode">94010</ix:nonNumeric></span></b></span></p></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt"><b>(Address of principal executive offices, including Zip Code)</b></span></td></tr>
</table>
<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><b>Registrant's telephone number, including
area code: (<span id="xdx_90D_edei--CityAreaCode_c20210212__20210212_zYDmf7ZJySM1"><ix:nonNumeric contextRef="From2021-02-12to2021-02-12" name="dei:CityAreaCode">650</ix:nonNumeric></span>) <span id="xdx_90D_edei--LocalPhoneNumber_c20210212__20210212_zeBb5OrLwhI4"><ix:nonNumeric contextRef="From2021-02-12to2021-02-12" name="dei:LocalPhoneNumber">900-4520</ix:nonNumeric></span></b></p>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_905_edei--WrittenCommunications_c20210212__20210212_z3nHKqWCZi33"><ix:nonNumeric contextRef="From2021-02-12to2021-02-12" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify">Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)</td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_907_edei--SolicitingMaterial_c20210212__20210212_zdOJnKOOFrI1"><ix:nonNumeric contextRef="From2021-02-12to2021-02-12" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)</td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_90E_edei--PreCommencementTenderOffer_c20210212__20210212_zCncGHOEupd4"><ix:nonNumeric contextRef="From2021-02-12to2021-02-12" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_908_edei--PreCommencementIssuerTenderOffer_c20210212__20210212_zy3bEedEzaHg"><ix:nonNumeric contextRef="From2021-02-12to2021-02-12" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</td>
</tr></table>


<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border: Black 1pt solid; width: 35%; text-align: center; white-space: nowrap"><span style="font-size: 10pt">Title of each class</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 31%; text-align: center; white-space: nowrap"><span style="font-size: 10pt">Trading symbol(s)</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 34%; text-align: center; white-space: nowrap"><span style="font-size: 10pt">Name of each exchange on which registered</span></td></tr>
<tr style="vertical-align: top; background-color: white">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; white-space: nowrap"><span style="font-size: 10pt"><span id="xdx_900_edei--Security12bTitle_c20210212__20210212_zG0tvlK7RFzj"><ix:nonNumeric contextRef="From2021-02-12to2021-02-12" name="dei:Security12bTitle">Common Stock, Par Value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; white-space: nowrap"><span style="font-size: 10pt"><span id="xdx_909_edei--TradingSymbol_c20210212__20210212_zXw7w8ARXGz2"><ix:nonNumeric contextRef="From2021-02-12to2021-02-12" name="dei:TradingSymbol">CRVS</ix:nonNumeric></span></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; white-space: nowrap"><span style="font-size: 10pt"><span id="xdx_90B_edei--SecurityExchangeName_c20210212__20210212_zGNIbLZEzmbg"><ix:nonNumeric contextRef="From2021-02-12to2021-02-12" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq Global Market</ix:nonNumeric></span></span></td></tr>
</table>
<p style="margin: 0pt 0">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">Indicate by check mark whether the registrant is an emerging growth company as defined
in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule&#160;12b-2&#160;of the Securities Exchange Act of 1934
(17 CFR&#160;&#167;240.12b-2).&#160;Emerging growth company <span style="font-family: Wingdings"><span id="xdx_907_edei--EntityEmergingGrowthCompany_c20210212__20210212_zdvjWPlzDRFh"><ix:nonNumeric contextRef="From2021-02-12to2021-02-12" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">&#120;</ix:nonNumeric></span></span></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt">If an emerging growth company, indicate by check mark if the registrant has elected not
to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to
Section 13(a) of the Exchange Act. <span style="font-family: Wingdings"><span id="xdx_901_edei--EntityExTransitionPeriod_c20210212__20210212_zt0fl5XkwCLe"><ix:nonNumeric contextRef="From2021-02-12to2021-02-12" format="ixt:booleantrue" name="dei:EntityExTransitionPeriod">&#120;</ix:nonNumeric></span></span></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 0; font-size: 10pt"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0pt 0; font-size: 10pt"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 0.75in"><b>Item 8.01</b></td>
    <td><b>Other Events. </b></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On February 12, 2021, Corvus Pharmaceuticals, Inc. (&#8220;Corvus&#8221;
or the &#8220;Company&#8221;) entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Cantor Fitzgerald
&amp; Co. and H.C. Wainwright &amp; Co., LLC (the &#8220;Underwriters&#8221;), pursuant to which the Company agreed to issue and
sell 8,571,429 shares (the &#8220;Shares&#8221;) of its common stock, par value $0.0001 per share (&#8220;Common Stock&#8221;)
to the Underwriters (the &#8220;Offering)&#8221;. The Shares were sold at a price to the public of $3.50 per share, and were purchased
by the Underwriters from the Company at a price of $3.29 per Share. Under the terms of the Underwriting Agreement, the Company
granted the Underwriters the option, for 30 days, to purchase up to an additional 1,285,714 shares of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Offering was made under a prospectus supplement and related
prospectus filed with the Securities and Exchange Commission pursuant to the Company&#8217;s effective shelf registration statement
on Form S-3 (Registration No. 333-237040).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On February 17, 2021, the Offering closed and the Company
completed the sale and issuance of an aggregate of 9,783,660 shares of Common Stock, which includes 1,212,231 shares of common stock pursuant to the underwriters&#8217; partial exercise of their option to purchase additional
shares of common stock. The Company received net proceeds from
the Offering of approximately $31.8 million, after deducting the Underwriters&#8217; discounts and commissions and estimated
offering expenses payable by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the Underwriting Agreement, the Company agreed to
indemnify the Underwriter against certain liabilities, including liabilities under the Securities Act of 1933, as amended, or to
contribute to payments that the Underwriter may be required to make because of such liabilities. The Company and the Company&#8217;s
directors and executive officers also agreed not to sell or transfer any Common Stock for 90&#160;days after February 12, 2021
without first obtaining the written consent of the Underwriter, subject to certain exceptions as described in the prospectus supplement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A copy of the Underwriting Agreement is attached as Exhibit
1.1 hereto and is incorporated herein by reference. The foregoing descriptions of the Underwriting Agreement and lock-up arrangements
do not purport to be complete and are qualified in their entirety by reference to such exhibit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A copy of the opinion of Latham &amp; Watkins LLP relating to
the validity of the securities issued in the Offering is filed herewith as Exhibit 5.1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 0.75in"><b>Item&#160;9.01</b></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif"><b>Financial Statements and Exhibits. </b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">(d) Exhibits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 8%">
        <p style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exhibit&#160;No.</p></td>
    <td style="width: 1%">&#160;</td>
    <td style="white-space: nowrap">
        <p style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Description</p></td></tr>
<tr style="vertical-align: top">
    <td style="white-space: nowrap; font-size: 10pt"><a href="tm216892d1_ex1-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">1.1</span></a></td>
    <td>&#160;</td>
    <td style="font-size: 10pt"><a href="tm216892d1_ex1-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Underwriting Agreement, dated as of February 12, 2021, among Corvus Pharmaceuticals, Inc. and Cantor Fitzgerald &amp; Co. and H.C. Wainwright &amp; Co., LLC as the underwriters.</span></a></td></tr>
<tr style="vertical-align: top">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td>&#160;</td>
    <td style="font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="white-space: nowrap; font-size: 10pt"><a href="tm216892d1_ex5-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">5.1</span></a></td>
    <td>&#160;</td>
    <td style="font-size: 10pt"><a href="tm216892d1_ex5-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Opinion of Latham &amp; Watkins LLP.</span></a></td></tr>
<tr style="vertical-align: top">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td>&#160;</td>
    <td style="font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="white-space: nowrap; font-size: 10pt"><a href="tm216892d1_ex5-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">23.1</span></a></td>
    <td>&#160;</td>
    <td style="font-size: 10pt"><a href="tm216892d1_ex5-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Consent of Latham &amp; Watkins LLP (included in Exhibit 5.1).</span></a></td></tr>
<tr style="vertical-align: top">
    <td style="white-space: nowrap; font-size: 10pt">&#160;</td>
    <td>&#160;</td>
    <td style="font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="white-space: nowrap; font-size: 10pt">104</td>
    <td>&#160;</td>
    <td style="font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td>&#160;</td>
<td colspan="2"><span style="font-size: 10pt"><b>CORVUS PHARMACEUTICALS, INC.</b></span></td></tr>
<tr style="vertical-align: top">
<td>&#160;</td>
<td colspan="2">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="width: 50%"><span style="font-size: 10pt">Date: February 17, 2021</span></td>
<td style="width: 3%">By:</td>
<td style="border-bottom: Black 1pt solid; width: 47%">/s/ Leiv Lea</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td>
<td>&#160;</td>
<td>Leiv Lea</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td>
<td>&#160;</td>
<td>Chief Financial Officer</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>



</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjU0KwkAMhU/QO4RZF53Wn0V3WrSIVaSIuB3aVAbbScmMf0fylo4tYgiE5L0vT4hQZLTWDTKcl0UOR2y7RjmEAmtkNCV6R7rZJuBngRdtHSvj+vUHpuQZ9MxsNCn9vXfetcUqATkfy+k4liDjZDqHxU4EXz0lU+sKjdOqAWUqODB1rNEpfg0fjupJhtpXn3RCtppMAtFIDvIbYhnFsKe7ehBfLeR5KoKwr0BkTLfuG3OzjlpYNdj6LDug/w4+1TtJCg== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>tm216892d1_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 1.1</B></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="text-align: right; margin: 0"><B>EXECUTION VERSION&nbsp;</B></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>8,571,429 Shares Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Corvus Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>UNDERWRITING AGREEMENT</U></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">February 12, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4in 0pt 0; text-align: left">c/o Cantor Fitzgerald &amp; Co.<BR>
499 Park Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4in 0pt 0; text-align: left">New York, NY 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4in 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4in 0pt 0; text-align: left">c/o H.C. Wainwright &amp; Co., LLC<BR>
430 Park Avenue<BR>
New York, NY 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4in 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1. <I>Introductory</I>. Corvus Pharmaceuticals,
Inc., a Delaware corporation (&ldquo;<B>Company</B>&rdquo;), agrees with the several Underwriters named in Schedule A hereto (&ldquo;<B>Underwriters</B>&rdquo;),
to issue and sell&nbsp;to the several Underwriters 8,571,429 shares (&ldquo;<B>Firm Shares</B>&rdquo;) of its common stock, par
value $0.0001 per share (&ldquo;<B>Common Stock</B>&rdquo;) and, at the option of the Underwriters, an aggregate of not more than
1,285,714 additional shares (&ldquo;<B>Optional Shares</B>&rdquo;) of its Common Stock as set forth below. The Firm Shares and
Optional Shares are herein collectively called the &ldquo;<B>Shares</B>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2. <I>Representations and Warranties of
the Company</I>. The Company represents and warrants to, and agrees with, the several Underwriters that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(a) <I>Filing and Effectiveness
of Registration Statement; Certain Defined Terms</I>. The Company has filed with the Commission a registration statement on Form
S-3 (No.&nbsp;333-237040), including a related prospectus or prospectuses, covering the registration of the Shares under the Act.
The &ldquo;<B>Registration Statement</B>&rdquo; at any particular time means such registration statement, in the form then on file
with the Commission, including any amendment thereto, any document incorporated by reference therein and all 430B Information and
all 430C Information with respect to such Registration Statement, that in any case has not then been superseded or modified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 18.2pt">As of the time
of execution and delivery of this Agreement, the Registration Statement has been declared effective under the Act and is not proposed
to be amended. The Shares all have been or will be duly registered under the Act pursuant to the Registration Statement. The effective
date of the Registration Statement was not earlier than the date three years before the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 18.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 18.2pt">For purposes
of this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 18.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in">&ldquo;<B>430B
Information</B>&rdquo;, with respect to any registration statement, means information included in a prospectus and then deemed
to be a part of such registration statement pursuant to Rule&nbsp;430B(e) or retroactively deemed to be a part of such registration
statement pursuant to Rule 430B(f).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in">&ldquo;<B>430C
Information</B>&rdquo;, with respect to any registration statement, means information included in a prospectus then deemed to be
a part of such registration statement pursuant to Rule&nbsp;430C.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in">&ldquo;<B>Act</B>&rdquo;
means the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in">&ldquo;<B>Applicable
Time</B>&rdquo; means 8:30 am (Eastern time) on the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in">&ldquo;<B>Closing
Date</B>&rdquo; has the meaning defined in Section 3 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in">&ldquo;<B>Commission</B>&rdquo;
means the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in">&ldquo;<B>Effective
Time</B>&rdquo; of the Registration Statement relating to the Shares means the time of the first contract of sale for the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in">&ldquo;<B>Exchange
Act</B>&rdquo; means the Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in">&ldquo;<B>Final
Prospectus</B>&rdquo; means the Statutory Prospectus that discloses the public offering price, other 430B Information and other
final terms of the Shares and otherwise satisfies Section&nbsp;10(a) of the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in">&ldquo;<B>General
Use Issuer Free Writing Prospectus</B>&rdquo; means any Issuer Free Writing Prospectus that is intended for general distribution
to prospective investors, as evidenced by its being so specified in Schedule B-1 to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in">&ldquo;<B>Issuer
Free Writing Prospectus</B>&rdquo; means any &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule&nbsp;433, relating
to the Shares in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained
in the Company&rsquo;s records pursuant to Rule&nbsp;433(g).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in">&ldquo;<B>Limited
Use Issuer Free Writing Prospectus</B>&rdquo; means any Issuer Free Writing Prospectus that is not a General Use Issuer Free Writing
Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in">A &ldquo;<B>Registration
Statement</B>&rdquo; without reference to a time means such Registration Statement as of its Effective Time. For purposes of the
foregoing definitions, 430B Information with respect to a Registration Statement shall be considered to be included in such Registration
Statement as of the time specified in Rule&nbsp;430B.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in">&ldquo;<B>Rules
and Regulations</B>&rdquo; means the rules and regulations of the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in">&ldquo;<B>Securities
Laws</B>&rdquo; means, collectively, the Sarbanes-Oxley Act of 2002 (&ldquo;<B>Sarbanes-Oxley</B>&rdquo;), the Act, the Exchange
Act, the Rules and Regulations, the auditing principles, rules, standards and practices applicable to auditors of &ldquo;issuers&rdquo;
(as defined in Sarbanes-Oxley) promulgated or approved by the Public Company Accounting Oversight Board and the rules of The Nasdaq
Stock Market LLC (&ldquo;<B>Exchange Rules</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in">&ldquo;<B>Statutory
Prospectus</B>&rdquo; with reference to a particular time means the prospectus relating to the Shares that is included in the Registration
Statement immediately prior to that time, including any 430B&nbsp;Information or 430C Information with respect to such Registration
Statement. For purposes of the foregoing definition, 430B Information shall be considered to be included in the Statutory Prospectus
only as of the actual time that form of prospectus (including a prospectus supplement) is filed with the Commission pursuant to
Rule&nbsp;424(b) and not retroactively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in">&ldquo;<B>Testing-the-Waters
Communication</B>&rdquo; means any oral or written communication with potential investors undertaken in reliance on either Section
5(d) of the Act or Rule 163B of the Rules and Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in">&ldquo;<B>Written
Testing-the-Waters Communication</B>&rdquo; means any Testing-the-Waters Communication that is a written communication within the
meaning of Rule 405 under the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in">Unless otherwise
specified, a reference to a &ldquo;rule&rdquo; is to the indicated rule under the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(b) <I>Compliance with
Securities Act Requirements</I>. (i) (A) At the time the Registration Statement initially became effective, (B) at the time
of each amendment thereto for the purposes of complying with Section 10(a)(3) of the Act (whether by post-effective
amendment, incorporated report or form of prospectus), (C) at the Effective Time relating to the Shares and (D) on each
Closing Date, the Registration Statement conformed and will conform in all material respects to the requirements of the Act
and the Rules and Regulations and did not and will not include any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary to make the statements therein not misleading, and (ii)&nbsp;(A) on
its date, (B) at the time of filing of the Final Prospectus pursuant to Rule&nbsp;424(b), and (C) on each Closing Date, the
Final Prospectus will conform in all material respects to the requirements of the Act and the Rules and Regulations and will
not include any untrue statement of a material fact or omit to state any material fact required to be stated therein or
necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. The
preceding sentence does not apply to statements in or omissions from any such document based upon written information
furnished to the Company by or on behalf of any Underwriter specifically for use therein, it being understood and agreed that
the only such information is that described as such in Section 8(b) hereof. The Company meets the requirements for use of
Form S-3 under the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(c) <I>Ineligible Issuer Status</I>.
(i) At the earliest time after the filing of the Registration Statement that the Company or another offering participant made a
bona fide offer (within the meaning of Rule 164(h)(2)) of the Shares and (ii) at the date of this Agreement, the Company was not
and is not an &ldquo;ineligible issuer,&rdquo; as defined in Rule&nbsp;405, including (x)&nbsp;the Company or any subsidiary of
the Company in the preceding three years not having been convicted of a felony or misdemeanor or having been made the subject of
a judicial or administrative decree or order as described in Rule&nbsp;405 and (y)&nbsp;the Company in the preceding three years
not having been the subject of a bankruptcy petition or insolvency or similar proceeding, not having had a registration statement
be the subject of a proceeding under Section&nbsp;8 of the Act and not being the subject of a proceeding under Section&nbsp;8A
of the Act in connection with the offering of the Shares, all as described in Rule&nbsp;405.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(d) <I>General Disclosure Package</I>.
As of the Applicable Time, none of (i)&nbsp;the General Use Issuer Free Writing Prospectus(es) issued at or prior to the Applicable
Time, if any, the preliminary prospectus supplement, dated February 11, 2021, including the base prospectus dated March 9, 2020
(which is the most recent Statutory Prospectus distributed to investors generally) and the other information, if any, stated in
Schedule B-1 to this Agreement to be included in the General Disclosure Package, all considered together (collectively, the &ldquo;<B>General
Disclosure Package</B>&rdquo;), (ii)&nbsp;any individual Limited Use Issuer Free Writing Prospectus, when considered together with
the General Disclosure Package or (iii) any individual Written Testing-the-Waters Communication, when considered together with
the General Disclosure Package, included any untrue statement of a material fact or omitted to state any material fact necessary
in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The preceding
sentence does not apply to statements in or omissions from any Statutory Prospectus, any Issuer Free Writing Prospectus or any
Written Testing-the-Waters Communications, made in reliance upon and in conformity with written information furnished to the Company
by or on behalf of any Underwriter specifically for use therein, it being understood and agreed that the only such information
furnished by or on behalf of any Underwriter consists of the information described as such in Section&nbsp;8(b) hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(e) <I>Incorporated Documents</I>.
The documents incorporated by reference in the Registration Statement and the General Disclosure Package, when they were filed
or became effective with the Commission, conformed in all material respects to the requirements of the Exchange Act and the rules
and regulations thereunder and none of such documents contained any untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they
were made, not misleading; and any further documents so filed and incorporated by reference in the Registration Statement or the
General Disclosure Package, when such documents become effective or are filed with the Commission, as the case may be, will conform
in all material respects to the requirements of the Act or the Exchange Act, as applicable, and will not contain any untrue statement
of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein,
in the light of the circumstances under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(f) <I>Issuer Free Writing Prospectuses</I>.
Each Issuer Free Writing Prospectus, if any, as of its issue date and at all subsequent times through the completion of the public
offer and sale of the Shares or until any earlier date that the Company notified or notifies the Underwriters as described in the
next sentence, did not, does not and will not include any information that conflicted, conflicts or will conflict with the information
then contained in the Registration Statement. If at any time following issuance of an Issuer Free Writing Prospectus and prior
to the Closing Date there occurred or occurs an event or development as a result of which such Issuer Free Writing Prospectus conflicted
or would conflict with the information then contained in the Registration Statement or as a result of which such Issuer Free Writing
Prospectus, if republished immediately following such event or development, would include an untrue statement of a material fact
or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading, (i) the Company has promptly notified or will promptly notify the Underwriters and
(ii) the Company has promptly amended or will promptly amend or supplement such Issuer Free Writing Prospectus to eliminate or
correct such conflict, untrue statement or omission. The preceding sentence does not apply to statements in or omissions from any
Issuer Free Writing Prospectus made in reliance upon and in conformity with written information furnished to the Company by or
on behalf of any Underwriter specifically for use therein, it being understood and agreed that the only such information furnished
by or on behalf of any Underwriter consists of the information described as such in Section&nbsp;8(b) hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(g) <I>Good Standing of the Company</I>.
The Company has been duly incorporated and is existing and in good standing under the laws of the State of Delaware, with power
and authority (corporate and other) to own its properties and conduct its business as described in the General Disclosure Package
and the Final Prospectus; and the Company is duly qualified to do business as a foreign corporation in good standing in all other
jurisdictions in which its ownership or lease of property or the conduct of its business requires such qualification, except where
the failure to be so qualified or in good standing in such other jurisdictions would not, individually or in the aggregate, reasonably
be expected to result in a material adverse effect on the condition (financial or otherwise), results of operations, business,
properties or prospects of the Company and its subsidiaries, taken as a whole (&ldquo;<B>Material Adverse Effect</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(h) <I>Subsidiaries</I>. Each
subsidiary of the Company has been duly incorporated and is existing and in good standing under the laws of the jurisdictions of
its incorporation, with power and authority (corporate and other) to own its properties and conduct its business as described in
the General Disclosure Package; and each subsidiary of the Company is duly qualified to do business as a foreign corporation in
good standing in all other jurisdictions in which its ownership or lease of property or the conduct of its business requires such
qualification, except where the failure to be so qualified or in good standing in such other jurisdictions would not, individually
or in the aggregate, reasonably be expected to result in a Material Adverse Effect; all of the issued and outstanding capital stock
of each subsidiary of the Company has been duly authorized and validly issued and is fully paid and nonassessable; and the capital
stock of each subsidiary owned by the Company, directly or through subsidiaries, is owned free from liens, encumbrances and defects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(i) <I>The Securities</I>. The
Shares and all other outstanding shares of capital stock of the Company have been duly authorized; the authorized equity capitalization
of the Company is as set forth in the General Disclosure Package; all outstanding shares of capital stock of the Company are, and,
when the Shares have been delivered and paid for in accordance with this Agreement on each Closing Date, such Shares will have
been, validly issued, fully paid and nonassessable, will conform in all material respects to the information in the General Disclosure
Package and to the description of such Shares contained in the Final Prospectus; the stockholders of the Company have no preemptive
rights with respect to the Shares that have not been duly waived or satisfied; and none of the outstanding shares of capital stock
of the Company have been issued in violation of any preemptive or similar rights of any security holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(j) <I>No Finder&rsquo;s Fee</I>.
Except as disclosed in the General Disclosure Package and the Final Prospectus, there are no contracts, agreements or understandings
between the Company and any person that would give rise to a valid claim against the Company or any Underwriter for a brokerage
commission, finder&rsquo;s fee or other like payment in connection with this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(k) <I>Registration Rights</I>.
There are no contracts, agreements or understandings between the Company and any person granting such person the right to require
the Company to file a registration statement under the Act with respect to any securities of the Company owned or to be owned by
such person or to require the Company to include such securities in the securities registered pursuant to the Registration Statement
or in any securities being registered pursuant to any other registration statement filed by the Company under the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(l) <I>Listing</I>. The Shares
have been approved for listing on The Nasdaq Global Market, subject to notice of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(m) <I>Absence of Further Requirements</I>.
No consent, approval, authorization, or order of, or filing or registration with, any person (including any governmental agency
or body or any court) is required for the consummation of the transactions contemplated by this Agreement in connection with the
offering, issuance and sale of the Shares by the Company, except such as have been obtained, or made and such as may be required
under state securities laws or the Financial Industry Regulatory Authority (&ldquo;<B>FINRA</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(n) <I>Title to Property</I>.
Except as disclosed in the General Disclosure Package and the Final Prospectus or as would not reasonably be expected to result
in a Material Adverse Effect, the Company and its subsidiaries have good and marketable title to all personal property and assets
owned by them, in each case free from liens, charges, encumbrances and defects, and the Company and its subsidiaries hold any leased
real or personal property under valid and enforceable leases with no terms or provisions that would materially interfere with the
use made or to be made thereof by them. Neither the Company nor any of its subsidiaries own any real property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(o) <I>Absence of Defaults and
Conflicts Resulting from Transaction</I>. The execution, delivery and performance of this Agreement, and the issuance and sale
of the Shares will not result in a breach or violation of any of the terms and provisions of, or constitute a default or a Debt
Repayment Triggering Event (as defined below) under, or result in the imposition of any lien, charge or encumbrance upon any property
or assets of the Company or any of its subsidiaries pursuant to, (i) the charter or bylaws of the Company or any of its subsidiaries,
(ii) any statute, rule, regulation or order of any governmental agency or body or any court, domestic or foreign, having jurisdiction
over the Company, any of its subsidiaries or any of their properties, or (iii) any agreement or instrument to which the Company
or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any of the properties
of the Company or any of its subsidiaries is subject, except in the case of each of clauses (ii) and (iii), where such breaches,
violations, defaults, liens, charges or encumbrances would not, individually or in the aggregate, reasonably be expected to result
in a Material Adverse Effect; a &ldquo;<B>Debt Repayment Triggering Event</B>&rdquo; means any event or condition that gives, or
with the giving of notice or lapse of time would give, the holder of any note, debenture, or other evidence of indebtedness (or
any person acting on such holder&rsquo;s behalf) the right to require the repurchase, redemption or repayment of all or a portion
of such indebtedness by the Company or any of its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(p) <I>Absence of Existing
Defaults and Conflicts</I>. Neither the Company nor any of its subsidiaries is in violation of its respective charter or
bylaws or in default (or with the giving of notice or lapse of time would be in default) under any existing obligation,
agreement, covenant or condition contained in any indenture, loan agreement, mortgage, lease or other agreement or instrument
to which any of them is a party or by which any of them is bound or to which any of the properties of any of them is subject,
except such defaults that would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse
Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(q) <I>Authorization of Agreement</I>.
This Agreement has been duly authorized, executed and delivered by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(r) <I>Possession of Licenses
and Permits</I>. Except in such cases that would not reasonably be expected to result in a Material Adverse Effect, the Company
and its subsidiaries possess, and are in compliance with the terms of, all adequate certificates, authorizations, franchises, licenses
and permits (&ldquo;<B>Licenses</B>&rdquo;) necessary or material to the conduct of the business now conducted or proposed in the
General Disclosure Package and the Final Prospectus to be conducted by them, including, without limitation, from the U.S. Food
and Drug Administration (&ldquo;<B>FDA</B>&rdquo;) and neither the Company nor any of its subsidiaries has received any notice
of proceedings relating to the revocation or modification of any Licenses that, if determined adversely to the Company and or any
of its subsidiaries, would, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(s) <I>Absence of Labor Dispute</I>.
No labor dispute with the employees of the Company or any of its subsidiaries exists or, to the knowledge of the Company, is imminent
that would reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(t) <I>Intellectual
Property</I>. Except as would not reasonably be expected to have a Material Adverse Effect or as otherwise expressly
disclosed in the General Disclosure Package and the Final Prospectus, the Company and its subsidiaries own or have obtained
valid and enforceable licenses for, or otherwise have the right to use, all patents, patent applications, inventions,
copyrights, know how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential
information, systems or procedures), trademark registrations and applications for registration, service marks, trade names,
domain names, and other similar intellectual property or proprietary rights, whether or not registered (including all
goodwill associated with the foregoing, as applicable) (collectively, &ldquo;<B>Intellectual Property Rights</B>&rdquo;)
necessary and material to the conduct of the business now conducted by them. To the Company&rsquo;s knowledge the conduct of
the business of the Company and its subsidiaries has not conflicted with, infringed, misappropriated or otherwise violated
any Intellectual Property Rights of any third party. Except as expressly disclosed in the General Disclosure Package and the
Final Prospectus: (i) there are no claims asserted in writing by third parties to ownership of any of the Intellectual
Property Rights owned by the Company or any of its subsidiaries; (ii) to the Company&rsquo;s knowledge, all issued patents
contained within the Intellectual Property Rights owned or licensed by the Company or any of its subsidiaries are valid and
enforceable, solely owned or licensed by the Company or its subsidiaries and, to the extent owned, are owned free and clear
of all liens and encumbrances; (iii) to the Company&rsquo;s knowledge, without any duty to conduct a special search, there is
no material infringement, misappropriation, breach, default or other violation by any third party of any of the Intellectual
Property Rights owned by or licensed to the Company or any of its subsidiaries; (iv) there is no pending or, to the
Company&rsquo;s knowledge, without any duty to conduct a special search, threatened action, suit, proceeding or claim by
others challenging the rights of the Company or any of its subsidiaries in or to the Intellectual Property Rights owned by or
licensed to the Company or any of its subsidiaries; (v) there is no pending or, to the Company&rsquo;s knowledge, without any
duty to conduct a special search, threatened action, suit, proceeding or claim by others challenging the validity,
enforceability or scope of any such Intellectual Property Rights; (vi) there is no pending or, to the Company&rsquo;s
knowledge, without any duty to conduct a special search, threatened action, suit, proceeding or claim by others that the
Company or any of its subsidiaries infringes, misappropriates or otherwise violates any Intellectual Property Rights or other
proprietary rights of others and the Company is unaware of any other fact which would form a reasonable basis for any such
claim; and (vii) none of the Intellectual Property Rights used by the Company or any of its subsidiaries in their respective
businesses has been obtained or is being used by the Company or any of its subsidiaries in violation of any contractual
obligation binding on the Company or any of its subsidiaries, except in each case covered by clauses (i)&nbsp;&ndash;
(vii)&nbsp;such as would not, if determined adversely to the Company and its subsidiaries, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(u) <I>Environmental Laws</I>.
Except as disclosed in the General Disclosure Package and the Final Prospectus, neither the Company nor any of its subsidiaries
is in violation of any statute, any rule, regulation, decision or order of any governmental agency or body or any court, domestic
or foreign, relating to the use, disposal or release of hazardous or toxic substances or relating to the protection or restoration
of the environment or human exposure to hazardous or toxic substances (collectively, &ldquo;<B>environmental laws</B>&rdquo;),
the Company and its subsidiaries do not own or operate any real property contaminated with any substance that is subject to any
environmental laws, are not liable for any off-site disposal or contamination pursuant to any environmental laws, and are not subject
to any claim relating to any environmental laws, which violation, contamination, liability or claim would, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect; and the Company is not aware of any pending investigation
which might lead to such a claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(v) <I>Accurate Disclosure</I>.
The statements in the General Disclosure Package and the Final Prospectus under the headings &ldquo;Material U.S. Federal Income
Tax Consequences to Non-U.S. Holders&rdquo;, &ldquo;Description of Capital Stock&rdquo;, &ldquo;Business&mdash;Regulation&rdquo;,
 &ldquo;Business&mdash;Intellectual property&rdquo;, &ldquo;Risk Factors&mdash;Risks Related to Our Intellectual Property&rdquo;
and &ldquo;Risk Factors&mdash;Risks related to Commercialization of Our Product Candidates&rdquo;, insofar as such statements summarize
legal matters, agreements, documents or proceedings discussed therein, are accurate and fair summaries of such legal matters, agreements,
documents or proceedings in all material respects and present the information required to be shown in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(w) <I>Absence of Manipulation</I>.
The Company has not taken, directly or indirectly, any action that is designed to or that has constituted or that would reasonably
be expected to cause or result in the stabilization or manipulation of the price of any security of the Company to facilitate the
sale or resale of the Shares; provided, that no representation is made in this subsection with respect to the actions of the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(x) <I>Statistical and Market-Related
Data</I>. Any third-party statistical and market-related data included in a Registration Statement, a Statutory Prospectus, the
General Disclosure Package or any Written Testing-the-Waters Communications is based on or derived from sources that the Company
believes to be reliable and accurate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(y) <I>Internal Controls and
Compliance with the Sarbanes-Oxley Act</I>. Except as set forth in the General Disclosure Package and the Final Prospectus, the
Company, its subsidiaries and the Company&rsquo;s Board of Directors (the &ldquo;<B>Board</B>&rdquo;) are in compliance with the
applicable provisions of Sarbanes-Oxley and all applicable Exchange Rules. The Company maintains a system of &ldquo;internal controls
over financial reporting&rdquo; (as defined in Rule 13a-15(f) of the Exchange Act), including, but not limited to, disclosure
controls and procedures and internal controls over accounting matters and financial reporting and legal and regulatory compliance
controls (collectively, &ldquo;<B>Internal Controls</B>&rdquo;) comply with the Securities Laws (to the extent applicable) and
are sufficient to provide reasonable assurances that (i) transactions are executed in accordance with management&rsquo;s general
or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity
with U.S. Generally Accepted Accounting Principles (&ldquo;<B>GAAP</B>&rdquo;) and to maintain accountability for assets, (iii)
access to assets is permitted only in accordance with management&rsquo;s general or specific authorization and (iv) the recorded
accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect
to any differences. The Internal Controls are, or upon consummation of the offering of the Shares will be, overseen by the Audit
Committee (the &ldquo;<B>Audit Committee</B>&rdquo;) of the Board in accordance with Exchange Rules. Except as disclosed to the
Underwriters, the Company has not publicly disclosed or reported to the Audit Committee or the Board, and within the next 135
days the Company does not reasonably expect to publicly disclose or report to the Audit Committee or the Board, a &ldquo;significant
deficiency&rdquo;, &ldquo;material weakness&rdquo; (each as defined in Rule 12b-2 of the Exchange Act), adverse change in Internal
Controls or fraud involving management or other employees who have a significant role in Internal Controls (each, an &ldquo;Internal
Control Event&rdquo;), or any violation of, or failure to comply with, the Securities Laws, which, if determined adversely, would
have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(z) <I>Litigation</I>. Except
as disclosed in the General Disclosure Package and the Final Prospectus, there are no pending actions, suits or proceedings (including,
to the Company&rsquo;s knowledge, any inquiries or investigations by any court or governmental agency or body, domestic or foreign)
against or affecting the Company, any of its subsidiaries or any of their respective properties that, if determined adversely to
the Company or any of its subsidiaries, would, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect, or would materially and adversely affect the ability of the Company to perform its obligations under this Agreement, or
which are otherwise material in the context of the sale of the Shares; and no such actions, suits or proceedings (including, to
the Company&rsquo;s knowledge, any inquiries or investigations by any court or governmental agency or body, domestic or foreign)
are threatened or, to the Company&rsquo;s knowledge, contemplated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(aa) <I>Financial Statements</I>.
The financial statements included in each Registration Statement, the General Disclosure Package and the Final Prospectus present
fairly in all material respects the financial position of the Company and its consolidated subsidiaries as of the dates shown and
their results of operations and cash flows for the periods shown, and such financial statements have been prepared in conformity
with GAAP, applied on a consistent basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(bb) <I>Auditor Independence.
</I>PricewaterhouseCoopers LLP, who has certified certain financial statements of the Company, is an independent registered public
accounting firm with respect to the Company within the applicable rules and regulations adopted by the Commission and the Public
Company Accounting Oversight Board (United States) and as required by the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(cc) <I>No Material Adverse Change
in Business</I>. Except as disclosed in the General Disclosure Package and the Final Prospectus, since the end of the period covered
by the latest audited financial statements included in the General Disclosure Package and the Final Prospectus (i) there has been
no change, nor any development or event involving a prospective change, that would reasonably be expected to result in a Material
Adverse Effect , (ii) except as disclosed in or contemplated by the General Disclosure Package and the Final Prospectus, there
has been no dividend or distribution of any kind declared, paid or made by the Company on any class of its capital stock and (iii)
except as disclosed in or contemplated by the General Disclosure Package and the Final Prospectus, there has been no material adverse
change in the capital stock, short-term indebtedness, long-term indebtedness, net current assets or net assets of the Company and
its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(dd) <I>Investment Company Act</I>.
The Company is not and, after giving effect to the offering and sale of the Shares and the application of the proceeds thereof
as described in the General Disclosure Package and the Final Prospectus, will not be an &ldquo;investment company&rdquo; as defined
in the Investment Company Act of 1940, as amended (the &ldquo;<B>Investment Company Act</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(ee) <I>Ratings</I>. The Company
does not have any debt securities or preferred stock that are rated by any &ldquo;nationally recognized statistical rating agency&rdquo;
(as defined in Section 3(a)(62) of the Exchange Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(gg) <I>Compliance</I>. Neither
the Company, nor any of its subsidiaries, nor any of its officers or directors, nor, to the Company&rsquo;s knowledge, any affiliate,
employee, agent or representative of the Company or any of its subsidiaries or of any of its affiliates, has violated any of the
following laws: (a) anti-bribery laws, including but not limited to, any applicable law, rule, or regulation of any locality, including
but not limited to any law, rule, or regulation promulgated to implement the OECD Convention on Combating Bribery of Foreign Public
Officials in International Business Transactions, signed December 17, 1997, including the U.S. Foreign Corrupt Practices Act of
1977, as amended or any other law, rule or regulation of similar purpose and scope, (b) anti-money laundering laws, including but
not limited to, applicable federal, state, international, foreign or other laws, regulations or government guidance regarding anti-money
laundering, including, without limitation, Title 18 U.S. Code section 1956 and 1957, the Patriot Act, the Bank Secrecy Act, and
international anti-money laundering principals or procedures by an intergovernmental group or organization, such as the Financial
Action Task Force on Money Laundering, of which the United States is a member and with which designation the United States representative
to the group or organization continues to concur, all as amended, and any Executive order, directive, or regulation pursuant to
the authority of any of the foregoing, or any orders or licenses issued thereunder or (c) laws and regulations imposing U.S. economic
sanctions measures, including, but not limited to, the International Emergency Economic Powers Act, the Trading with the Enemy
Act, the United Nations Participation Act, and the Syria Accountability and Lebanese Sovereignty Act, all as amended, and any Executive
Order, directive, or regulation pursuant to the authority of any of the foregoing, including the regulations of the United States
Treasury Department set forth under 31 CFR, Subtitle B, Chapter V, as amended, or any orders or licenses issued thereunder. The
Company&rsquo;s participation in the offering will not violate any of the foregoing laws and the Company and its subsidiaries have
instituted and maintained, and will continue to maintain, policies and procedures reasonably designed to promote and achieve compliance
with such laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(hh) <I>FDA</I>. The Company
has operated and currently is in compliance with all applicable rules, regulations and policies of the FDA, except where the failure
to so operate or be in compliance would not reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(ii) <I>Clinical Trials</I>.
Any clinical trials and human studies conducted by the Company and, to the knowledge of the Company, any clinical trials and human
studies conducted on behalf of the Company or in which the Company has participated, with respect to the Company&rsquo;s product
candidates, were, and if still pending are, being conducted in accordance with all applicable rules, regulations and policies of
the FDA and comparable regulatory agencies outside of the United States to which the Company is subject and current Good Clinical
Practices and Good Laboratory Practices, except where the failure to be so conducted would not reasonably be expected to have a
Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(jj) <I>Taxes</I>. The Company
has filed all federal, state, local and non-U.S. tax returns that are required to be filed through the date of this Agreement or
have obtained extensions thereof (except in any case in which the failure to file would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect) and have paid all taxes required to be paid thereon, including any assessments,
fines or penalties related thereto (except for any such taxes, assessments, fines or penalties being contested in good faith for
which reserves required by GAAP have been created in the financial statements of the Company, or, except in any case in which the
failure to file or pay would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect);
and no tax deficiency has been determined adversely to the Company which has had (nor does the Company have any notice or knowledge
of any tax deficiency which could reasonably be expected to be determined adversely to the Company and which would reasonably be
expected to have) a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(kk) <I>Insurance</I>. The Company
is insured by insurers with appropriately rated claims paying abilities against such losses and risks and in such amounts as are
prudent and customary for similarly sized companies in the businesses in which it is engaged; all policies of insurance and fidelity
or surety bonds insuring the Company or its business, assets, employees, officers and directors are in full force and effect, except
as would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect; the Company is in
compliance with the terms of such policies and instruments in all material respects; and there are no claims by the Company under
any such policy or instrument as to which any insurance company is denying liability or defending under a reservation of rights
clause; the Company has not been refused any insurance coverage sought or applied for; the Company does not have any reason to
believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar
coverage from similar insurers as may be necessary to continue its business at a cost that would not reasonably be expected to
have a Material Adverse Effect, except as set forth in or contemplated in the General Disclosure Package and the Final Prospectus;
and the Company will obtain directors&rsquo; and officers&rsquo; insurance in such amounts as is customary for an initial public
offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3. <I>Purchase, Sale and Delivery of Shares</I>.
On the basis of the representations, warranties and agreements and subject to the terms and conditions set forth herein, the Company
agrees to sell to the several Underwriters, and each of the Underwriters agrees, severally and not jointly, to purchase from the
Company, at a purchase price of $3.29 per share, the number of shares of Firm Shares set forth opposite the names of the Underwriters
in Schedule A hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36.35pt">The Company will
deliver the Firm Shares to or as instructed by the Underwriters in a form reasonably acceptable to the Underwriters against payment
of the purchase price by the Underwriters in Federal (same day) funds by wire transfer to an account at a bank acceptable to the
Underwriters drawn to the order of the Company at the office of Davis Polk &amp; Wardwell LLP in Menlo Park, at 10:00 A.M., New
York time, on February 17, 2021, or at such other time not later than seven full business days thereafter as the Underwriters and
the Company determine, such time being herein referred to as the &ldquo;<B>First Closing Date</B>&rdquo;. For purposes of Rule&nbsp;15c6-1
under the Exchange Act, the First Closing Date (if later than the otherwise applicable settlement date) shall be the settlement
date for payment of funds and delivery of securities for all the Shares sold pursuant to the offering. The Firm Shares so to be
delivered or evidence of their issuance will be made available for checking at the office of Davis Polk &amp; Wardwell LLP at least
24&nbsp;hours prior to the First Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36.35pt">In addition, upon
written notice from the Underwriters given to the Company from time to time not more than 30 days subsequent to the date of the
Final Prospectus, the Underwriters may purchase all or less than all of the Optional Shares at the purchase price per Security
to be paid for the Firm Shares. The Company agrees to sell to the Underwriters the number of shares of Optional Shares specified
in such notice and the Underwriters agree, severally and not jointly to purchase such Optional Shares. Such Optional Shares shall
be purchased for the account of each Underwriter in the same proportion as the number of shares of Firm Shares set forth opposite
such Underwriter&rsquo;s name bears to the total number of shares of Firm Shares (subject to adjustment by the Underwriters to
eliminate fractions) and may be purchased by the Underwriters only for the purpose of covering over-allotments made in connection
with the sale of the Firm Shares. No Optional Shares shall be sold or delivered unless the Firm Shares and Warrants previously
have been, or simultaneously are, sold and delivered. The right to purchase the Optional Shares or any portion thereof may be exercised
from time to time during the 30-day period following the date of the Final Prospectus and to the extent not previously exercised
may be surrendered and terminated at any time upon notice by the Underwriters to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36.35pt">Each time for
the delivery of and payment for the Optional Shares, being herein referred to as an &ldquo;<B>Optional Closing
Date</B>&rdquo;, which may be the First Closing Date (the First Closing Date and each Optional Closing Date, if any, being
sometimes referred to as a &ldquo;<B>Closing Date</B>&rdquo;), shall be determined by the Underwriters but, except as
otherwise mutually agreed between the Company and the Underwriters, shall be not less than two full business days nor later
than five full business days after written notice of election to purchase Optional Shares is given, unless the Optional
Closing Date is the First Closing Date, in which case the Optional Closing Date may occur no sooner than one business day
after written notice of election is given. The Company will deliver the Optional Shares being purchased on each Optional
Closing Date to or as instructed by the Underwriters in a form reasonably acceptable to the Underwriters against payment of
the purchase price therefor in Federal (same day) funds by wire transfer to an account at a bank acceptable to the
Underwriters drawn to the order of the Company, at the office of Davis Polk &amp; Wardwell LLP in Menlo Park. The Optional
Shares being purchased on each Optional Closing Date or evidence of their issuance will be made available for checking at the
office of Davis Polk &amp; Wardwell LLP at a reasonable time in advance of such Optional Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4. <I>Offering by Underwriters</I>. It is
understood that the several Underwriters propose to offer the Shares for sale to the public as set forth in the Final Prospectus.
The Company and the Underwriters agree that the Underwriters may engage in passive market making transactions in the Shares on
The Nasdaq Global Market in accordance with Regulation M under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5. <I>Certain Agreements of the Company</I>.
The Company agrees with the several Underwriters that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(a) <I>Additional Filings</I>.
The Company will file the Final Prospectus, in a form approved by the Underwriters, with the Commission pursuant to and in accordance
with Rule&nbsp;424(b) not later than the second business day following the execution and delivery of this Agreement. The Company
will advise the Underwriters promptly of any such filing pursuant to Rule&nbsp;424(b) and provide satisfactory evidence to the
Underwriters of such timely filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(b) <I>Filing of Amendments;
Response to Commission Requests</I>. The Company will promptly advise the Underwriters of any proposal to amend or supplement at
any time the Registration Statement or any Statutory Prospectus at any time prior to the later of (i) completion of the distribution
of the Shares within the meaning of the Act and (ii) completion of the Lock-Up Period and will not effect such amendment or supplement
without the Underwriters&rsquo; consent, which consent shall not be unreasonably delayed or withheld; and the Company will also
advise the Underwriters promptly of (i) any amendment or supplement of a Registration Statement or any Statutory Prospectus, (ii)
any request by the Commission or its staff for any amendment to any Registration Statement, for any supplement to any Statutory
Prospectus or for any additional information, (iii) the institution by the Commission of any stop order proceedings in respect
of a Registration Statement or the threatening of any proceeding for that purpose, and (iv) the receipt by the Company of any notification
with respect to the suspension of the qualification of the Shares in any jurisdiction or the institution or threatening of any
proceedings for such purpose. The Company will use its reasonable best efforts to prevent the issuance of any such stop order or
the suspension of any such qualification and, if issued, to obtain as soon as possible the withdrawal thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(c) <I>Continued Compliance with
Securities Laws</I>. If, at any time when a prospectus relating to the Shares is (or but for the exemption in Rule&nbsp;172 would
be) required to be delivered under the Act by any Underwriter or any dealer, any event occurs as a result of which the Final Prospectus
as then amended or supplemented would include an untrue statement of a material fact or omit to state any material fact necessary
to make the statements therein, in the light of the circumstances under which they were made, not misleading, or if it is necessary
at any time to amend the Registration Statement or supplement the Final Prospectus to comply with the Act, the Company will promptly
notify the Underwriters of such event and will promptly prepare and file with the Commission and furnish, at its own expense, to
the Underwriters and the dealers and any other dealers upon request of the Underwriters, an amendment or supplement which will
correct such statement or omission or an amendment which will effect such compliance. Neither the Underwriters&rsquo; consent to,
nor the Underwriters&rsquo; delivery of, any such amendment or supplement shall constitute a waiver of any of the conditions set
forth in Section&nbsp;7 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(d) <I>Emerging Growth Company
Status</I>. The Company will promptly notify the Underwriters if the Company ceases to be an Emerging Growth Company at any time
prior to the later of (a) completion of the distribution of the Shares within the meaning of the Securities Act and (b) completion
of the 90-day restricted period referred to in Section 5(m) hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(e) <I>Rule&nbsp;158</I>. As
soon as practicable, but not later than the Availability Date (as defined below), the Company will make generally available to
its securityholders an earnings statement covering a period of at least 12 months beginning after the Effective Time of the Registration
Statement which will satisfy the provisions of Section&nbsp;11(a) of the Act and Rule&nbsp;158 under the Act. For the purpose of
the preceding sentence, &ldquo;<B>Availability Date</B>&rdquo; means the day after the end of the fourth fiscal quarter following
the fiscal quarter that includes such Effective Time on which the Company is required to file its Form 10-Q for such fiscal quarter
except that, if such fourth fiscal quarter is the last quarter of the Company&rsquo;s fiscal year, &ldquo;<B>Availability Date</B>&rdquo;
means the day after the end of such fourth fiscal quarter on which the Company is required to file its Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(f) <I>Furnishing of Prospectuses</I>.
The Company will furnish to the Underwriters copies of each Registration Statement, each related Statutory Prospectus, and, so
long as a prospectus relating to the Shares is (or but for the exemption in Rule&nbsp;172 would be) required to be delivered under
the Act, the Final Prospectus and all amendments and supplements to such documents, in each case in such quantities as the Underwriters
reasonably request. The Final Prospectus shall be so furnished on or prior to 3:00&nbsp;P.M., Eastern time, on the second business
day following the execution and delivery of this Agreement, unless otherwise agreed by the Company and the Underwriters. All other
documents shall be so furnished as soon as available. The Company will pay the expenses of printing and distributing to the Underwriters
all such documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(g) <I>Blue Sky Qualifications</I>.
The Company will arrange for the qualification of the Shares for sale under (or obtain exemption from the application of) the laws
of such jurisdictions as the Underwriters reasonably designate and will continue such qualifications and exemptions in effect so
long as required for the distribution, provided that the Company will not be required to qualify as a foreign corporation in any
jurisdiction in which it is not so qualified or file a general consent to service of process in any such jurisdiction or take any
action that would subject it to taxation in any such jurisdiction where it is not then so subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(h) <I>Testing-the-Waters</I>.
If at any time following the distribution of any Written Testing-the-Waters Communication there occurred or occurs an event or
development as a result of which such Written Testing-the-Waters Communication included or would include an untrue statement of
a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light
of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Underwriters and will
promptly amend or supplement, at its own expense, such Written Testing-the-Waters Communication to eliminate or correct such untrue
statement or omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(i) <I>Reporting Requirements</I>.
During the period expiring on the date that is two years hereafter, the Company will furnish to the Underwriters as soon as practicable
after the end of each fiscal year, a copy of its annual report to stockholders for such year; and the Company will furnish to the
Underwriters (i) as soon as available, a copy of each report and any definitive proxy statement of the Company filed with the Commission
under the Exchange Act or mailed to stockholders, and (ii) from time to time, such other non-confidential information concerning
the Company as the Underwriters may reasonably request. However, so long as the Company is subject to the reporting requirements
of either Section 13 or Section 15(d) of the Exchange Act and is timely filing reports with the Commission on its Electronic Data
Gathering, Analysis and Retrieval system (or any successor system), it is not required to furnish such reports or statements to
the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(j) <I>Payment of Expenses</I>.
The Company will pay all expenses incident to the performance of its obligations under this Agreement, including but not limited
to (i) any filing fees and other expenses (including reasonably incurred and documented fees and disbursements of counsel to the
Underwriters) incurred in connection with qualification of the Shares for sale under the laws of such jurisdictions as the Underwriters
designate, (ii) the preparation and printing of memoranda relating thereto, costs and expenses related to the review by FINRA of
the Shares (including filing fees and the reasonably incurred and documented fees and expenses of counsel for the Underwriters
relating to such review up to $20,000), (iii) costs and expenses relating to investor presentations or any &ldquo;road show&rdquo;
in connection with the offering and sale of the Shares including, without limitation, any travel expenses of the Company&rsquo;s
officers and employees and (iv) any other expenses of the Company, fees and expenses incident to listing the Shares on The Nasdaq
Global Market, fees and expenses in connection with the registration of the Shares under the Exchange Act, and expenses incurred
in distributing preliminary prospectuses and the Final Prospectus (including any amendments and supplements thereto) to the Underwriters
and for expenses incurred for preparing, printing and distributing any Issuer Free Writing Prospectuses to investors or prospective
investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(k) <I>Use of Proceeds</I>. The
Company will use the net proceeds received in connection with the offering of the Shares in the manner described in the &ldquo;Use
of Proceeds&rdquo; section of the General Disclosure Package and, except as disclosed in the General Disclosure Package and the
Final Prospectus, the Company does not intend to use any of the proceeds from the sale of the Shares hereunder to repay any outstanding
debt owed to any Underwriter or affiliate of any Underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(l) <I>Absence of Manipulation</I>.
The Company will not take, directly or indirectly, any action designed to or that would constitute or that might reasonably be
expected to cause or result in, stabilization or manipulation of the price of any securities of the Company to facilitate the sale
or resale of the Shares; provided, that no agreement is made in this subsection with respect to the actions of the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(m) <I>Restriction on Sale
of Securities. </I>For the period specified below (the &ldquo;<B>Lock-Up Period</B>&rdquo;), the Company will not, directly
or indirectly, take any of the following actions with respect to its Common Stock or any securities convertible into or
exchangeable or exercisable for any of its Common Stock (&ldquo;<B>Lock-Up Securities</B>&rdquo;): (i) offer, sell, issue,
contract to sell, pledge or otherwise dispose of Lock-Up Securities, (ii) offer, sell, issue, contract to sell, contract to
purchase or grant any option, right or warrant to purchase Lock-Up Securities, (iii) enter into any swap, hedge or any other
agreement that transfers, in whole or in part, the economic consequences of ownership of Lock-Up Securities, (iv) establish
or increase a put equivalent position or liquidate or decrease a call equivalent position in Lock-Up Securities within the
meaning of Section 16 of the Exchange Act or (v) file with the Commission a registration statement under the Act relating to
Lock-Up Securities (other than registration statements on Form S-8 relating to Lock-Up Securities granted or to be granted
pursuant to the terms of a plan disclosed in the General Disclosure Package), or publicly disclose the intention to take any
such action, without the prior written consent of the Underwriters, except, with respect to each of clauses (i) through (v),
for (A) grants of employee stock options or other equity-based awards pursuant to the terms of a plan disclosed in the
General Disclosure Package, (B) issuances of Lock-Up Securities pursuant to the exercise of such options or other
equity-based awards, (C) issuances of Lock-Up Securities pursuant to the conversion or exchange of convertible or
exchangeable securities (including cashless or &ldquo;net&rdquo; exercises) or the exercise of options or vesting of
restricted stock, in each case, outstanding on the date hereof, (D) the sale or issuance of Lock-Up Securities in connection
with a debt or credit financing facility or equipment leasing arrangement, (E) the sale or issuance of or entry into an
agreement to sell or issue Lock-Up Securities in connection with any (1) mergers, (2) acquisition of securities, businesses,
property or other assets, (3) joint ventures or (4) collaborations, licensing or strategic alliances; <U>provided</U>, that
the aggregate number of shares of Common Stock (on as-converted or as-exercised basis, as the case may be) that the Company
may sell or issue or agree to sell or issue pursuant to clauses (D) or (E) in this Section 5(m), in each case, shall not
exceed 5% of the total number of shares of the Company&rsquo;s Common Stock issued and outstanding immediately following the
completion of the transaction contemplated by this Agreement, (F) the issuance of the Shares, or (G) following the date that
is 30 days after the date of the Final Prospectus, any Common Stock sold through an &ldquo;at-the-market&rdquo; or similar
offering conducted by or on behalf of the Company, including pursuant to that certain Sales Agreement, dated March 9, 2020,
by and between the Company and Jefferies LLC; provided, that in the case of clauses (D) and (E), the recipients of such
Lock-Up Securities agree to (x) be bound by a lockup letter in the form executed by directors, officers and stockholders
pursuant to Section 7(h) hereof and (y) enter stop transfer instructions for the Company&rsquo;s transfer agent and registrar
on such securities, which the Company agrees it will not waive or amend without the prior written consent of the
Underwriters, and provided further that in the case of clause (G), such Common Stock is sold at a price per share that is
greater that the public offering price per share in this offering. The Lock-Up Period will commence on the date hereof and
continue for 90 days after the date hereof or such earlier date that the Underwriters consent to in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">6. <I>Issuer Free Writing Prospectuses</I>.
The Company represents and agrees that, unless it obtains the prior consent of the Underwriters, and each Underwriter represents
and agrees that, unless it obtains the prior consent of the Company and the other Underwriters, it has not made and will not make
any offer relating to the Shares that would constitute an Issuer Free Writing Prospectus, or that would otherwise constitute a
 &ldquo;free writing prospectus,&rdquo; as defined in Rule&nbsp;405, required to be filed with the Commission. Any such free writing
prospectus consented to by the Company and the Underwriters is hereinafter referred to as a &ldquo;<B>Permitted Free Writing Prospectus</B>.&rdquo;
The Company represents that it has treated and agrees that it will treat each Permitted Free Writing Prospectus as an &ldquo;issuer
free writing prospectus,&rdquo; as defined in Rule&nbsp;433, and has complied and will comply with the requirements of Rules&nbsp;164
and&nbsp;433 applicable to any Permitted Free Writing Prospectus, including timely Commission filing where required, legending
and record keeping. The Company represents that it has satisfied and agrees that it will satisfy the conditions in Rule&nbsp;433
to avoid a requirement to file with the Commission any electronic road show.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">7. <I>Conditions of the Obligations of the
Underwriters</I>. The obligations of the several Underwriters to purchase and pay for the Firm Shares on the First Closing Date
and the Optional Shares to be purchased on each Optional Closing Date will be subject to the accuracy of the representations and
warranties of the Company herein (as though made on such Closing Date), to the accuracy of the statements of Company officers made
pursuant to the provisions hereof, to the performance by the Company of its obligations hereunder and to the following additional
conditions precedent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(a) <I>Accountants&rsquo; Comfort
Letter</I>. The Underwriters shall have received letters, dated, respectively, the date hereof and each Closing Date, of PricewaterhouseCoopers
LLP confirming that they are a registered public accounting firm and independent public accountants within the meaning of the Securities
Laws and in form and substance satisfactory to the Underwriters (except that, in any letter dated a Closing Date, the specified
date referred to in such letter hereto shall be a date no more than three days prior to such Closing Date).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(b) <I>CFO Certificate</I>. The
Underwriters shall have received certificates, dated, respectively, the date hereof and each Closing Date, of the chief financial
officer of the Company confirming the accuracy of certain financial and other information included in the preliminary prospectus
supplement, dated February 11, 2021 and the Final Prospectus, in form and substance reasonably satisfactory to the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(c) <I>Effectiveness of Registration
Statement</I>. The Final Prospectus shall have been filed with the Commission in accordance with the Rules and Regulations and
Section&nbsp;5(a) hereof. Prior to such Closing Date, no stop order suspending the effectiveness of a Registration Statement shall
have been issued and no proceedings for that purpose shall have been instituted or, to the knowledge of the Company or the Underwriters,
shall be threatened by the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(d) <I>No Material Adverse Change</I>.
Subsequent to the execution and delivery of this Agreement, there shall not have occurred (i) any change, or any development or
event involving a prospective change, in the condition (financial or otherwise), results of operations, business, properties or
prospects of the Company and its subsidiaries, taken as a whole, which, in the judgment of the Underwriters, is material and adverse
and makes it impractical or inadvisable to market the Shares; (ii) any change in either U.S. or international financial, political
or economic conditions or currency exchange rates or exchange controls the effect of which is such as to make it, in the judgment
of the Underwriters, impractical to market or to enforce contracts for the sale of the Shares, whether in the primary market or
in respect of dealings in the secondary market; (iii) any suspension or material limitation of trading in securities generally
on the New York Stock Exchange or The Nasdaq Global Market, or any setting of minimum or maximum prices for trading on such exchange;
(iv) or any suspension of trading of any securities of the Company on any exchange or in the over-the-counter market; (v) any banking
moratorium declared by any U.S. federal or New York authorities; (vi) any major disruption of settlements of securities, payment,
or clearance services in the United States or any other country where such securities are listed or (vii) any attack on, outbreak
or escalation of hostilities or act of terrorism involving the United States, any declaration of war by Congress or any other national
or international calamity or emergency if, in the judgment of the Underwriters, the effect of any such attack, outbreak, escalation,
act, declaration, calamity or emergency is such as to make it impractical or inadvisable to market the Shares or to enforce contracts
for the sale of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(e) <I>Opinion of Counsel for
Company</I>. The Underwriters shall have received an opinion and a negative assurance letter, and an opinion as to certain tax
matters, each dated such Closing Date, of Latham &amp; Watkins LLP, counsel for the Company, in form and substance agreed upon
between the parties (with appropriate modification to the date and number of Common Stock for any opinion or negative assurance
letter delivered on any Optional Closing Date), together with signed or reproduced copies of such letters for each of the other
Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(f) <I>Opinion of Intellectual
Property Counsel for Company</I>. The Underwriters shall have received an opinion and a negative assurance letter, each dated such
Closing Date, of Mintz Levin Cohn Ferris Glovsky and Popeo PC, intellectual property counsel for the Company, in form and substance
agreed upon between the parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(g) <I>Opinion of Counsel for
Underwriters. </I>The Underwriters shall have received from Davis Polk &amp; Wardwell LLP, counsel for the Underwriters, such opinion
or opinions and a negative assurance letter, dated such Closing Date, with respect to such matters as the Underwriters may require,
and the Company shall have furnished to such counsel such documents as they request for the purpose of enabling them to pass upon
such matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(h) <I>Officers&rsquo; Certificate</I>.
The Underwriters shall have received a certificate, dated such Closing Date, of an executive officer of the Company and a principal
financial or accounting officer of the Company in their capacities as officers of the Company in which such officers shall state
that: the representations and warranties of the Company in this Agreement are true and correct; the Company has complied with all
agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to such Closing Date; no
stop order suspending the effectiveness of any Registration Statement has been issued and no proceedings for that purpose have
been instituted or, to the best of their knowledge, are contemplated by the Commission; and, subsequent to the date of the most
recent financial statements in the General Disclosure Package and the Final Prospectus, there has been no material adverse change,
nor any development or event involving a prospective material adverse change, in the condition (financial or otherwise), results
of operations, business, properties or prospects of the Company and its subsidiaries taken as a whole except as set forth in the
General Disclosure Package and the Final Prospectus or as described in such certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>




<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(i) <I>Lock-up Agreements</I>.
On or prior to the date hereof, the Underwriters shall have received lock-up agreements in substantially the form set forth on
Exhibit A hereto from each of the executive officers, directors and holders of the outstanding equity securities of the Company
set forth on Annex I to Exhibit A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company will furnish the Underwriters
with such conformed copies of such opinions, certificates, letters and documents as the Underwriters reasonably request. The Underwriters
may in their sole discretion waive compliance with any conditions to the obligations of the Underwriters hereunder, whether in
respect of an Optional Closing Date or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">8. <I>Indemnification and Contribution</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(a) <I>Indemnification of Underwriters</I>.
The Company will indemnify and hold harmless each Underwriter, its partners, members, directors, officers, employees, agents, affiliates
and each person, if any, who controls such Underwriter within the meaning of Section 15 of the Act or Section 20 of the Exchange
Act (each, an &ldquo;<B>Indemnified Party</B>&rdquo;), against any and all losses, claims, damages or liabilities, joint or several,
to which such Indemnified Party may become subject, under the Act, the Exchange Act, other Federal or state statutory law or regulation
or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based
upon any untrue statement or alleged untrue statement of any material fact contained in any part of any Registration Statement
at any time, any Statutory Prospectus as of any time, the Final Prospectus, any Issuer Free Writing Prospectus or any Written Testing-the-Waters
Communication, or arise out of or are based upon the omission or alleged omission of a material fact required to be stated therein
or necessary to make the statements therein, in light of the circumstances in which they were made, not misleading, and will reimburse
each Indemnified Party for any legal or other expenses reasonably incurred by such Indemnified Party in connection with investigating
or defending against any loss, claim, damage, liability, action, litigation, investigation or proceeding whatsoever (whether or
not such Indemnified Party is a party thereto), whether threatened or commenced, and in connection with the enforcement of this
provision with respect to any of the above as such expenses are incurred; provided, however, that the Company will not be liable
in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon an untrue statement
or alleged untrue statement in or omission or alleged omission from any of such documents made in reliance upon and in conformity
with written information furnished to the Company by or on behalf of any Underwriter specifically for use therein, it being understood
and agreed that the only such information furnished by any Underwriter consists of the information described as such in subsection
(b) below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b) <I>Indemnification of
Company</I>. Each Underwriter will severally and not jointly indemnify and hold harmless the Company, each of its directors
and each of its officers who signs a Registration Statement and each person, if any, who controls the Company within the
meaning of Section 15 of the Act or Section 20 of the Exchange Act (each, an &ldquo;<B>Underwriter Indemnified
Party</B>&rdquo;), against any losses, claims, damages or liabilities to which such Underwriter Indemnified Party may become
subject, under the Act, the Exchange Act, other Federal or state statutory law or regulation or otherwise, insofar as such
losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any untrue statement or
alleged untrue statement of any material fact contained in any part of any Registration Statement at any time, any Statutory
Prospectus as of any time, the Final Prospectus, any Issuer Free Writing Prospectus or any Written Testing-the-Waters
Communication, or arise out of or are based upon the omission or the alleged omission of a material fact required to be
stated therein or necessary to make the statements therein, in light of the circumstances in which they were made, not
misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or
omission or alleged omission was made in reliance upon and in conformity with written information furnished to the Company by
such Underwriter specifically for use therein, and will reimburse any legal or other expenses reasonably incurred by such
Underwriter Indemnified Party in connection with investigating or defending against any such loss, claim, damage, liability,
action, litigation, investigation or proceeding whatsoever (whether or not such Underwriter Indemnified Party is a party
thereto), whether threatened or commenced, based upon any such untrue statement or omission, or any such alleged untrue
statement or omission as such expenses are incurred, it being understood and agreed that the only such information furnished
by or on behalf of any Underwriter consists of the following information in the &ldquo;Underwriting&rdquo; section of the
Final Prospectus furnished on behalf of each Underwriter: the fifth paragraph (beginning &ldquo;Shares sold by the
underwriters&hellip;&rdquo;), and eleventh paragraph (beginning &ldquo;In connection with the offering, the underwriters may
purchase and sell shares&hellip;&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(c) <I>Actions against Parties;
Notification</I>. Promptly after receipt by an indemnified party under this Section of notice of the commencement of any action,
such indemnified party will, if a claim in respect thereof is to be made against the indemnifying party under subsection (a) or
(b) above, notify the indemnifying party of the commencement thereof; but the failure to notify the indemnifying party shall not
relieve it from any liability that it may have under subsection (a) or (b) above except to the extent that it has been materially
prejudiced (through the forfeiture of substantive rights or defenses) by such failure; and provided further that the failure to
notify the indemnifying party shall not relieve it from any liability that it may have to an indemnified party otherwise than under
subsection (a) or (b) above. In case any such action is brought against any indemnified party and it notifies the indemnifying
party of the commencement thereof, the indemnifying party will be entitled to participate therein and, to the extent that it may
wish, jointly with any other indemnifying party similarly notified, to assume the defense thereof, with counsel satisfactory to
such indemnified party (who shall not, except with the consent of the indemnified party, be counsel to the indemnifying party),
and after notice from the indemnifying party to such indemnified party of its election so to assume the defense thereof, the indemnifying
party will not be liable to such indemnified party under this Section for any legal or other expenses subsequently incurred by
such indemnified party in connection with the defense thereof other than reasonable costs of investigation. No indemnifying party
shall, without the prior written consent of the indemnified party, effect any settlement of any pending or threatened action in
respect of which any indemnified party is or could have been a party and indemnity could have been sought hereunder by such indemnified
party unless such settlement (i)&nbsp;includes an unconditional release of such indemnified party from all liability on any claims
that are the subject matter of such action and (ii)&nbsp;does not include a statement as to, or an admission of, fault, culpability
or a failure to act by or on behalf of an indemnified party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(d) <I>Contribution</I>. If
the indemnification provided for in this Section is unavailable or insufficient to hold harmless an indemnified party under
subsection (a) or (b) above, then each indemnifying party shall contribute to the amount paid or payable by such indemnified
party as a result of the losses, claims, damages or liabilities referred to in subsection (a) or (b) above (i)&nbsp;in such
proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and the Underwriters on
the other from the offering of the Shares or (ii)&nbsp;if the allocation provided by clause (i)&nbsp;above is not permitted
by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause
(i)&nbsp;above but also the relative fault of the Company on the one hand and the Underwriters on the other in connection
with the statements or omissions which resulted in such losses, claims, damages or liabilities as well as any other relevant
equitable considerations. The relative benefits received by the Company on the one hand and the Underwriters on the other
shall be deemed to be in the same proportion as the total net proceeds from the offering (before deducting expenses) received
by the Company bear to the total underwriting discounts and commissions received by the Underwriters. The relative fault
shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or
the omission or alleged omission to state a material fact relates to information supplied by the Company or the Underwriters
and the parties&rsquo; relative intent, knowledge, access to information and opportunity to correct or prevent such untrue
statement or omission. The amount paid by an indemnified party as a result of the losses, claims, damages or liabilities
referred to in the first sentence of this subsection (d) shall be deemed to include any legal or other expenses reasonably
incurred by such indemnified party in connection with investigating or defending any action or claim which is the subject of
this subsection (d). Notwithstanding the provisions of this subsection (d), no Underwriter shall be required to contribute
any amount in excess of the amount by which the total price at which the Shares underwritten by it and distributed to the
public were offered to the public exceeds the amount of any damages which such Underwriter has otherwise been required to pay
by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Act) shall be entitled to contribution from any person who was
not guilty of such fraudulent misrepresentation. The Underwriters&rsquo; obligations in this subsection (d) to contribute are
several in proportion to their respective underwriting obligations and not joint. The Company and the Underwriters agree that
it would not be just and equitable if contribution pursuant to this Section 8(d) were determined by pro rata allocation (even
if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take
account of the equitable considerations referred to in this Section 8(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">9. <I>Default of Underwriters</I>. If any
Underwriter or Underwriters default in their obligations to purchase Shares hereunder on either the First Closing Date or any Optional
Closing Date and the aggregate number of shares of Shares that such defaulting Underwriter or Underwriters agreed but failed to
purchase does not exceed 10% of the total number of shares of Shares that the Underwriters are obligated to purchase on such Closing
Date, Underwriters may make arrangements satisfactory to the Company for the purchase of such Shares by other persons, including
any of the Underwriters, but if no such arrangements are made by such Closing Date, the non-defaulting Underwriters shall be obligated
severally, in proportion to their respective commitments hereunder, to purchase the Shares that such defaulting Underwriters agreed
but failed to purchase on such Closing Date. If any Underwriter or Underwriters so default and the aggregate number of shares of
Shares with respect to which such default or defaults occur exceeds 10% of the total number of shares of Shares that the Underwriters
are obligated to purchase on such Closing Date and arrangements satisfactory to Underwriters and the Company for the purchase of
such Shares by other persons are not made within 36 hours after such default, or if arrangements satisfactory to the Company for
the purchase of the Shares referred to in the first sentence of this Section 9 by other persons are not made within 36 hours after
such default, this Agreement will terminate without liability on the part of any non-defaulting Underwriter or the Company, except
as provided in Section&nbsp;10 (provided that if such default occurs with respect to Optional Shares after the First Closing Date,
this Agreement will not terminate as to the Firm Shares or any Optional Shares purchased prior to such termination). As used in
this Agreement, the term &ldquo;Underwriter&rdquo; includes any person substituted for an Underwriter under this Section. Nothing
herein will relieve a defaulting Underwriter from liability for its default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">10. <I>Survival of Certain Representations
and Obligations</I>. The respective indemnities, agreements, representations, warranties and other statements of the Company or
its officers and of the Underwriters set forth in or made pursuant to this Agreement will remain in full force and effect, regardless
of any investigation, or statement as to the results thereof, made by or on behalf of any Underwriter, the Company or any of their
respective representatives, officers or directors or any controlling person, and will survive delivery of and payment for the Shares.
If the purchase of the Shares by the Underwriters is not consummated for any reason other than because of the termination of this
Agreement pursuant to Section&nbsp;9 hereof or as a result of any event set forth in Section 7(c)(ii), (iii), (v), (vi) or (vii),
the Company will reimburse the Underwriters for all reasonably incurred and documented out-of-pocket expenses (including fees and
disbursements of counsel) reasonably incurred by them in connection with the offering of the Shares, and the respective obligations
of the Company and the Underwriters pursuant to Section 8 hereof shall remain in effect. In addition, if any Shares have been purchased
hereunder, the representations and warranties in Section 2 and all obligations under Section 5 shall also remain in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Split-Segment; Name: a1 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">11. <I>Notices</I>. All communications
hereunder will be in writing and, if sent to the Underwriters, will be mailed, delivered or telegraphed and confirmed to the
Underwriters in care of <FONT STYLE="background-color: white">Cantor Fitzgerald &amp; Co., </FONT>499 Park Avenue, New York,
NY 10022, Attention: General Counsel, facsimile: (212) 829-4708 and in care of H.C. Wainwright &amp; Co. LLC, 430 Park
Avenue, 4<SUP>th </SUP>Floor, New York, NY 10022, Attention: Head of Investment Banking, facsimile: (212) 214-0803 or, if
sent to the Company, will be mailed, delivered or telegraphed and confirmed to it at 863 Mitten Road, Suite 102, Burlingame,
California 94010; Attention: Chief Financial Officer, with a copy to (which copy shall not constitute notice), Latham &amp;
Watkins LLP, 140 Scott Drive, Menlo Park, California 94025; Attention: Alan C. Mendelson, Esq; provided, however, that any
notice to an Underwriter pursuant to Section 8 will be mailed, delivered or telegraphed and confirmed to such
Underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">12. <I>Successors</I>. This Agreement will
inure to the benefit of and be binding upon the parties hereto and their respective successors and the officers and directors and
controlling persons referred to in Section&nbsp;8, and no other person will have any right or obligation hereunder.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">13. <I>Counterparts</I>. This Agreement
may be executed in any number of counterparts, each of which shall be deemed to be an original, but all such counterparts shall
together constitute one and the same Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">14. <I>Absence of Fiduciary Relationship.
</I>The Company acknowledges and agrees that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(a) <I>No Other Relationship</I>.
The Underwriters have been retained solely to act as underwriters in connection with the sale of Shares and that no fiduciary,
advisory or agency relationship between the Company and the Underwriters has been created in respect of any of the transactions
contemplated by this Agreement or the Final Prospectus, irrespective of whether the Underwriters have advised or is advising the
Company on other matters;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(b) <I>Arms&rsquo; Length Negotiations</I>.
The price of the Shares set forth in this Agreement was established by the Company following discussions and arms-length negotiations
with the Underwriters and the Company is capable of evaluating and understanding and understands and accepts the terms, risks and
conditions of the transactions contemplated by this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(c) <I>Absence of Obligation
to Disclose</I>. The Company has been advised that the Underwriters and their respective affiliates are engaged in a broad range
of transactions which may involve interests that differ from those of the Company and that the Underwriters have no obligation
to disclose such interests and transactions to the Company by virtue of any fiduciary, advisory or agency relationship; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(d) <I>Waiver</I>. The Company
waives, to the fullest extent permitted by law, any claims it may have against the Underwriters for breach of fiduciary duty or
alleged breach of fiduciary duty and agrees that the Underwriters shall have no liability (whether direct or indirect) to the Company
in respect of such a fiduciary duty claim or to any person asserting a fiduciary duty claim on behalf of or in right of the Company,
including stockholders, employees or creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">15. <I>Applicable&nbsp;Law</I>. This Agreement
shall be governed by, and construed in accordance with, the laws of the State of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36.35pt">The Company hereby
submits to the non-exclusive jurisdiction of the Federal and state courts in the Borough of Manhattan in The City of New York in
any suit or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. The Company irrevocably
and unconditionally waives any objection to the laying of venue of any suit or proceeding arising out of or relating to this Agreement
or the transactions contemplated hereby in Federal and state courts in the Borough of Manhattan in The City of New York and irrevocably
and unconditionally waives and agrees not to plead or claim in any such court that any such suit or proceeding in any such court
has been brought in an inconvenient forum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.35pt"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.35pt">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">16. <I>Waiver of Jury Trial</I>. Each party
hereto hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any
legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">17. <I>Recognition of the U.S. Special Resolution
Regimes. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(a) In the event that any Underwriter
that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter
of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer
would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed
by the laws of the United States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">(b) In the event that any Underwriter
that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution
Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no
greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed
by the laws of the United States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">(c) As used in this section:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;BHC Act Affiliate&rdquo; has the
meaning assigned to the term &ldquo;affiliate&rdquo; in, and shall be interpreted in accordance with, 12 U.S.C. &sect; 1841(k).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;Covered Entity&rdquo; means any of
the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(i) a &ldquo;covered entity&rdquo; as that
term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 252.82(b);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(ii) a &ldquo;covered bank&rdquo; as that
term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 47.3(b); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(iii) a &ldquo;covered FSI&rdquo; as that
term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 382.2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;Default Right&rdquo; has the meaning
assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &sect;&sect; 252.81, 47.2 or 382.1, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;U.S. Special Resolution Regime&rdquo;
means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank
Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Value: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36.35pt">If the foregoing
is in accordance with the Underwriters&rsquo; understanding of our agreement, kindly sign and return to the Company one of the
counterparts hereof, whereupon it will become a binding agreement between the Company and the several Underwriters in accordance
with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.35pt">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="4" STYLE="text-align: center">Very truly yours,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify">CORVUS PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">By:&nbsp;&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: justify">/s/ Leiv Lea</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 5%">Name:</TD>
    <TD STYLE="text-align: justify; width: 43%">Leiv Lea</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Title:</TD>
    <TD STYLE="text-align: justify">Chief Financial Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 180.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[<I>Signature Page
to Underwriting Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 180.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 180.35pt"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 180.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">The
foregoing Underwriting Agreement is hereby<BR>
 confirmed and accepted as of the date first above<BR>
 written.</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: justify">CANTOR FITZGERALD &amp; CO.</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">By:&nbsp;&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: justify">/s/ Sage Kelly</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 5%">Name:</TD>
    <TD STYLE="text-align: justify; width: 43%">Sage Kelly</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Title:</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[<I>Signature Page
to Underwriting Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3in 0pt 17.85pt; text-align: justify; text-indent: -0.05pt"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3in 0pt 17.85pt; text-align: justify; text-indent: -0.05pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">The
foregoing Underwriting Agreement is hereby <BR>
confirmed and accepted as of the date first above <BR>
written.</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: justify">H.C. WAINWRIGHT &amp; CO., LLC</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">By:&nbsp;&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: justify">/s/ Edward D. Silvera</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 5%">Name:</TD>
    <TD STYLE="text-align: justify; width: 43%">Edward D. Silvera</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Title:</TD>
    <TD STYLE="text-align: justify">Chief Operating Officer</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[<I>Signature Page
to Underwriting Agreement</I>]</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Underwriter</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <BR> Firm Shares</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; font-size: 10pt; text-align: justify">Cantor Fitzgerald &amp; Co.</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">6,000,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt">H.C. Wainwright &amp; Co., LLC</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,571,429</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt; padding-left: 0.125in">Total</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">8,571,429</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE B-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>1.</B></TD><TD STYLE="text-align: left"><B>General Use Free Writing Prospectuses (included in the General Disclosure Package)</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;General Use
Issuer Free Writing Prospectus&rdquo; includes each of the following documents:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">1. None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>2.</B></TD><TD STYLE="text-align: left"><B>Other Information Included in the General Disclosure Package</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following information
is also included in the General Disclosure Package:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">1. The initial price to the public
of the Shares shall be $3.50.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">2. The Company is selling 8,571,429
shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">3. The Company has granted an
option to the Underwriters, severally and not jointly, to purchase up to an additional 1,285,714 shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE B-2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Written Testing-the-Waters Communications</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">None</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form of Lock-up</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">Date: ________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Corvus Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">863 Mitten Road Suite 102</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Burlingame, CA 94010</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">c/o Cantor Fitzgerald &amp; Co.<BR>
499 Park Avenue<BR>
New York, NY 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4in 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4in 0pt 0; text-align: left">c/o H.C. Wainwright &amp; Co., LLC<BR>
430 Park Avenue<BR>
New York, NY 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4in 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies &amp; Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">As an inducement to the
Underwriters to execute the Underwriting Agreement (the &ldquo;<B>Underwriting Agreement</B>&rdquo;), pursuant to which an offering
(&ldquo;<B>Offering</B>&rdquo;) will be made of the common stock, par value $0.0001 (the &ldquo;<B>Securities</B>&rdquo;) of Corvus
Pharmaceuticals, Inc. (the &ldquo;<B>Company</B>&rdquo;), the undersigned hereby agrees that during the period commencing on the
date of this Lock-Up Agreement (this &ldquo;<B>Lock-Up Agreement</B>&rdquo;) and ending 90 days after the public offering date
set forth on the final prospectus used to sell the Securities (the &ldquo;<B>Public Offering Date</B>&rdquo;) pursuant to the
Underwriting Agreement, to which you are or expect to become parties (the &ldquo;<B>Lock-Up Period</B>&rdquo;), the undersigned
will not offer, sell, contract to sell, pledge or otherwise dispose of, directly or indirectly, any Securities or securities convertible
into or exchangeable or exercisable for any Securities, enter into a transaction which would have the same effect, or engage in
any hedging or other transaction or arrangement (including, without limitation, any short sale or the purchase or sale of, or
entry into, any put or call option, or combination thereof, forward, swap or any other derivative transaction or instrument, however
described or defined) which is designed to or which reasonably could be expected to lead to or result in a sale, loan, pledge
or other disposition (whether by the undersigned or someone other than the undersigned), or transfer of any of the economic consequences
of ownership, in whole or in part, directly or indirectly, whether any such aforementioned transaction is to be settled by delivery
of the Securities or such other securities, in cash or otherwise, or publicly disclose the intention to make any such offer, sale,
pledge or disposition, or to enter into any such hedge, transaction or other arrangement, without, in each case, the prior written
consent of Cantor Fitzgerald &amp; Co. (&ldquo;<B>Cantor</B>&rdquo;), in each case, other than (A) transfers of Securities or
other securities as a bona fide gift or gifts or by testate succession or intestate distribution, (B) any Securities acquired
by the undersigned in the Offering or on the open market following the Offering, (C) the exercise of stock options or other similar
awards granted pursuant to the Company&rsquo;s equity incentive plans, provided that such restriction shall apply to any of the
Securities issued to the undersigned upon such exercise, (D) any Securities or other securities that are transferred to the Company
for the primary purpose of satisfying any tax or other governmental withholding obligation, through cashless surrender or otherwise,
with respect to any award of equity-based compensation granted pursuant to the Company&rsquo;s equity incentive plans or in connection
with tax or other obligations as a result of testate succession or intestate distribution, (E) the establishment or amendment
of any contract, instruction or plan that satisfies all of the requirements of Rule 10b5-1(c)(1)(i)(B) under the Securities Exchange
Act of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;) (such a contract, instruction or plan, a &ldquo;<B>Plan</B>&rdquo;),
provided that no sales of the undersigned&rsquo;s Securities shall be made pursuant to such a Plan prior to the expiration of
the Lock-Up Period referred to above, (F) the sale or transfer of Securities or any security convertible into Securities pursuant
to a Plan in effect and disclosed to Cantor prior to the execution of this Agreement by the undersigned (such Plan, an &ldquo;<B>Existing
Plan</B>&rdquo;), provided, that if the undersigned reports any such sale or transfer on Form 4 under Section 16(a) of the Exchange
Act, the undersigned shall cause such Form 4 to include a statement that such transfer was effected pursuant to an Existing Plan
that was in effect on the date that the undersigned executed this Letter Agreement, (G) transfers not involving a disposition
for value to a member or members of the undersigned&rsquo;s family or to a trust, the direct or indirect beneficiaries of which
are the undersigned and/or a member or members of his or her family, (H) transfers or dispositions of the Undersigned&rsquo;s
Securities by will, other testamentary document or intestate succession to the legal representative, heir, beneficiary or a member
of the immediate family of the undersigned, (I) distributions not involving a disposition for value of Securities or other securities
to members, partners or stockholders of the undersigned or to any corporation, partnership or other person or entity that is a
direct or indirect affiliate of the undersigned (including, for the avoidance of doubt, a fund managed by the same manager or
managing member or general partner or management company or by an entity controlling, controlled by, or under common control with
such manager or managing member or general partner or management company as the undersigned or who shares a common investment
advisor with the undersigned), (J) the transfer or disposition of the undersigned&rsquo;s Securities or other securities that
occurs by operation of law, such as pursuant to a qualified domestic order or in connection with a divorce settlement, (K) if
the undersigned is an investment company registered under the Investment Company Act of 1940, as amended (a &ldquo;<B>Mutual Fund</B>&rdquo;),
transfers of the undersigned&rsquo;s Securities pursuant to a merger or reorganization with or into another Mutual Fund that shares
the same investment adviser registered pursuant to the requirements of the Investment Advisers Act of 1940, as amended and (L)
the transfer of the undersigned&rsquo;s Securities or other securities to the Company pursuant to any contractual arrangement
in effect on the date of this Lock-Up Agreement that provides for the repurchase of the undersigned&rsquo;s Securities or such
other securities by the Company or in connection with the termination of the undersigned&rsquo;s employment or other service relationship
with the Company; provided that in the case of any transfer or distribution pursuant to clause (A), (G), (H), (I), (J) or (K),
each donee, distributee or transferee shall execute and deliver to Cantor a lock-up letter in the form of this paragraph; and
provided, further, that in the case of any transfer or distribution pursuant to clause (A), (B), (D), (E), or (G) through (J),
no filing by any party (donor, donee, transferor or transferee) under Section 16 of the Exchange Act, or other public announcement
shall be required or shall be made voluntarily in connection with such transfer or distribution (other than a filing on a Form
5 made after the expiration of the Lock-Up Period referred to above and other than disclosures required by Form 13F, Schedule
13D or Schedule 13G that are not (x) triggered by a specific transaction and (y) required to be filed during the Lock-Up Period).
In addition, the undersigned agrees that, without the prior written consent of Cantor, it will not, during the Lock-Up Period,
make any demand for or exercise any right with respect to, the registration of any Securities or any security convertible into
or exercisable or exchangeable for the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The restrictions contained
herein shall not apply to any transfers, sales, tenders or other dispositions of Securities or any security convertible into or
exercisable or exchangeable for Securities pursuant to a bona fide third party tender offer made to all holders of the Company&rsquo;s
common stock or a merger, amalgamation, consolidation or other similar transaction, in each case that is approved by the Board
of Directors of the Company and that is on substantially the same terms for holders of at least 50.1% of the outstanding common
stock of the Company, the result of which is that any &ldquo;person&rdquo; (as defined in Section 13(d)(3) of the Exchange Act),
or group of persons, other than the Company, becomes the beneficial owner (as defined in Rules 13d-3 and 13d-5 of the Exchange
Act) of 50% of total voting power of the voting stock of the Company (including, without limitation, the entering into any lock-up,
voting or similar agreement pursuant to which the undersigned may agree to transfer, sell, tender or otherwise dispose of Securities
or other such securities in connection with such transaction, or vote any Securities or other such securities in favor of any such
transaction); provided that if such tender offer, merger, amalgamation, consolidation or other similar transaction is not completed,
any Securities or any security convertible into or exercisable or exchangeable for Securities subject to this Lock-Up Agreement
shall remain subject to the restrictions contained in this Lock-Up Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In furtherance of the
foregoing, the Company and its transfer agent and registrar are hereby authorized to decline to make any transfer of shares of
Securities if such transfer would constitute a violation or breach of this Lock-Up Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">This Lock-Up Agreement
shall be binding on the undersigned and the successors, heirs, personal representatives and assigns of the undersigned. This Lock-Up
Agreement shall lapse and become null and void if the Public Offering Date shall not have occurred on or before March 31, 2021.
The undersigned understands that (i) on March 31, 2021 if the Public Offering Date shall not have occurred, (ii) if the Underwriting
Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for
and delivery of the Securities to be sold thereunder, (iii) if Cantor, on the one hand, or the Company, on the other hand, informs
the other, prior to the execution of the Underwriting Agreement, that it has determined not to proceed with the Offering or (iv)
the registration statement related to the Offering has been completely withdrawn prior to the closing of the Offering, the undersigned
shall be released from all obligations under this Lock-Up Agreement. This Lock-Up Agreement and any claim, controversy or dispute
arising under or related to this Lock-Up Agreement shall be governed by, and construed in accordance with, the laws of the State
of New York, without regard to the conflicts of laws principles thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature page follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD COLSPAN="2" STYLE="text-indent: 0.5in; font-size: 10pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Very
    truly yours,</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>IF
    AN INDIVIDUAL:</B></FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>IF
    AN ENTITY:</B></FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-left: 0.25in; font-size: 10pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>(duly
    authorized signature)</I></FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>(please
    print complete name of entity)</I></FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-left: 0.375in; font-size: 10pt; text-align: left; width: 7%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; width: 42%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 2%">&nbsp;</TD>
    <TD STYLE="padding-left: 0.25in; font-size: 10pt; text-align: left; width: 8%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; width: 41%">&nbsp;</TD>
    </TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>&nbsp;&nbsp;&nbsp;&nbsp;(please
    print full name)</I></FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;<I>&nbsp;(duly
    authorized signature)</I></FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="padding-left: 0.375in; font-size: 10pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD>
    </TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>&nbsp;&nbsp;&nbsp;(please
    print full name)</I></FONT></TD></TR>

</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify; width: 10%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Email Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify; width: 39%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify; width: 10%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Email Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify; width: 39%">&nbsp;</TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Address:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Address:</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature Page to Lock-Up Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><U>Annex I</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Richard A. Miller, M.D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Ian T. Clark</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Elisha P. (Terry) Gould III</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Linda Grais</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">William B. Jones</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Steve E. Krognes</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Edith P. Mitchell</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Mehrdad Mobasher</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Scott W. Morrison</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Peter Thompson, M.D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Leiv Lea</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>tm216892d1_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 5.1</B></P>


<P STYLE="margin: 0; text-align: right">&nbsp;</P>


<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: middle; text-align: left; width: 60%; font-size: 10pt"><IMG SRC="tm216892d1_ex5-1img01.jpg" ALT="">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 40%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">140 Scott Drive</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Menlo Park, California 94025</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Tel: +1.650.328.4600 Fax: +1.650.463.2600</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">www.lw.com</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P></TD></TR>
</TABLE>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-top: 2pt; text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left">FIRM / AFFILIATE OFFICES</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-top: 2pt; text-align: left; width: 60%">&nbsp;</TD>
    <TD STYLE="padding-top: 2pt; width: 12%; font: 10pt Times New Roman, Times, Serif">Beijing</TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif; width: 28%">Moscow</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-top: 2pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif">Boston</TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif">Munich</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-top: 2pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif">Brussels</TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left">New York</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-top: 2pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left">Century City</TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left">Orange County</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-top: 2pt; text-align: left"><FONT STYLE="font-size: 10pt">February 17, 2021</FONT></TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif">Chicago</TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif">Paris</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-top: 2pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif">Dubai</TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif">Riyadh</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-top: 2pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif">D&uuml;sseldorf</TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left">San Diego</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-top: 2pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif">Frankfurt</TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left">San Francisco</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-top: 2pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif">Hamburg</TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif">Seoul</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-top: 2pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left">Hong Kong</TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif">Shanghai</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-top: 2pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif">Houston</TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left">Silicon Valley</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-top: 2pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif">London</TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif">Singapore</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-top: 2pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left">Los Angeles</TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif">Tokyo</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-top: 2pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif">Madrid</TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif; text-align: left">Washington, D.C.</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-top: 2pt; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif">Milan</TD>
    <TD STYLE="padding-top: 2pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
</TABLE>


<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Corvus Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">863 Mitten Road, Suite 102<BR>
Burlingame, CA 94010</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify; text-indent: -22.5pt">Re: <U>Registration
Statement No. 333-237040 on Form <BR>
S-3; Up to 9,783,660 shares of Common Stock, par value $0.0001 per share</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify; text-indent: -22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We have acted as
special counsel to Corvus Pharmaceuticals, Inc., a Delaware corporation (the &#8220;<B><I>Company</I></B>&#8221;), in
connection with the proposed issuance of up to 9,783,660 shares of common stock, $0.0001 par value per share (the
 &#8220;<B><I>Shares</I></B>&#8221;). The Shares are included in a registration statement on Form S-3 under the Securities Act
of 1933, as amended (the &#8220;<B><I>Act</I></B>&#8221;), filed with the Securities and Exchange Commission (the
 &#8220;<B><I>Commission</I></B>&#8221;) on March 9, 2020 (Registration No. 333-237040) (as amended, the
 &#8220;<B><I>Registration Statement</I></B>&#8221;), a base prospectus dated March 19, 2020 (the &#8220;<B><I>Base
Prospectus</I></B>&#8221;) and a prospectus supplement dated February 12, 2021 (together with the Base Prospectus, the
 &#8220;<B><I>Prospectus</I></B>&#8221;), and an underwriting agreement dated February 12, 2021, by and among Cantor
Fitzgerald &amp; Co. and H.C. Wainwright &amp; Co., LLC as underwriters, and the Company (the &#8220;<B><I>Underwriting
Agreement</I></B>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">This opinion is being
furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein
as to any matter pertaining to the contents of the Registration Statement or the Prospectus, other than as expressly stated herein
with respect to the issuance of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">As such counsel, we
have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your
consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without
having independently verified such factual matters. We are opining herein as to the General Corporation Law of the State of Delaware
(the &#8220;<B><I>DGCL</I></B>&#8221;), and we express no opinion with respect to any other laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Subject to the
foregoing and the other matters set forth herein, it is our opinion that, as of the date hereof, the Shares have been duly
authorized by all necessary corporate action of the Company, and, when the Shares shall have been duly registered on the
books of the transfer agent and registrar therefor in the name or on behalf of the purchasers, and have been issued by the
Company against payment therefor (not less than par value) in the circumstances contemplated by the Underwriting Agreement,
the Shares will be validly issued, fully paid and nonassessable. In rendering the foregoing opinion, we have assumed that the
Company will comply with all applicable notice requirements regarding uncertificated shares provided in the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">February 17,2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Page 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="tm216892d1_ex5-1img02.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">This opinion is for
your benefit in connection with the Registration Statement and the Prospectus and may be relied upon by you and by persons entitled
to rely upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the Company&#8217;s
Current Report on Form 8-K filed with the Commission on February 17, 2021 and to the reference to our firm in the Prospectus under
the heading &#8220;Legal Matters.&#8221; In giving such consent, we do not thereby admit that we are in the category of persons
whose consent is required under Section&nbsp;7 of the Act or the rules and regulations of the Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">/s/
    Latham &amp; Watikns LLP</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>crvs-20210212.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWa6HibOdzZR+SYkxtmB3bbnKTyYl2VPjISE5yNI2MRAF -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:crvs="http://corvuspharma.com/20210212" elementFormDefault="qualified" targetNamespace="http://corvuspharma.com/20210212">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://corvuspharma.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="crvs-20210212_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="crvs-20210212_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>crvs-20210212_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>crvs-20210212_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://corvuspharma.com/role/Cover" xlink:href="crvs-20210212.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://corvuspharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm216892d1_ex5-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm216892d1_ex5-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ? 18# 2(  A$! Q$!_\0
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MU_PDV@?]!S3?_ N/_&K5GJNG:@S+97]K<L@RPAF5\?7!KQGX@^#-*\-IH_\
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M!O7"D9_&M+8N,8XHE3<F[L*&+C0IQC&-Y7N[WZ;;,Y/X=:\WB'P=:7$I'VB
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3\HXSVHK3QBBJ22V,G)R=VS__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tm216892d1_ex5-1img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm216892d1_ex5-1img02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ? 18# 2(  A$! Q$!_\0
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MU_PDV@?]!S3?_ N/_&K5GJNG:@S+97]K<L@RPAF5\?7!KQGX@^#-*\-IH_\
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M!O7"D9_&M+8N,8XHE3<F[L*&+C0IQC&-Y7N[WZ;;,Y/X=:\WB'P=:7$I'VB
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3\HXSVHK3QBBJ22V,G)R=VS__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>tm216892d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="crvs-20210212.xsd" xlink:type="simple"/>
    <context id="From2021-02-12to2021-02-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001626971</identifier>
        </entity>
        <period>
            <startDate>2021-02-12</startDate>
            <endDate>2021-02-12</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-02-12to2021-02-12">0001626971</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-02-12to2021-02-12">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2021-02-12to2021-02-12">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2021-02-12to2021-02-12">2021-02-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2021-02-12to2021-02-12">CORVUS PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-02-12to2021-02-12">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2021-02-12to2021-02-12">001-37719</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-02-12to2021-02-12">46-4670809</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-02-12to2021-02-12">863 Mitten Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2021-02-12to2021-02-12">Suite 102</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2021-02-12to2021-02-12">Burlingame</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-02-12to2021-02-12">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-02-12to2021-02-12">94010</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-02-12to2021-02-12">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-02-12to2021-02-12">900-4520</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2021-02-12to2021-02-12">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2021-02-12to2021-02-12">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2021-02-12to2021-02-12">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2021-02-12to2021-02-12">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2021-02-12to2021-02-12">Common Stock, Par Value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-02-12to2021-02-12">CRVS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-02-12to2021-02-12">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-02-12to2021-02-12">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2021-02-12to2021-02-12">true</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140663183138072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Feb. 12, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 12,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CORVUS PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001626971<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-4670809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">863 Mitten Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Burlingame<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">900-4520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CRVS<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M^KZ^AH8/$L];,J=[_!EJ,:@W6]5C6)>E:H\_A?<HN9\;[O\2Q0]02P,$%
M  @ I(%14I>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q ?\70
MGC 'T"&(,V7Q%@3Y 5:B#]@2!8I%G;^OVJ5QD L9>3T\$MP>:4#M.*2VBZD8
M_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y +AEFM[UD%J=SI%>(
M7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1
MH2)8%II%R=.B':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^
M %!+ P04    " "D@5%2JL0B%C,!   B @  #P   'AL+W=O<FMB;V]K+GAM
M;(U1T6[", S\E2H?L!:T(0U17D#;D*8-C8GWT+K4(HDKQX6-KY_;JAK27O:4
MW-FZW%T6%^+3@>B4?'D78FYJD6:>IK&HP=MX1PT$G53$WHI"/J:Q8;!EK '$
MNW2:9;/46PQFN1BUMIS> A(H!"DHV1%[A$O\G7<P.6/$ SJ4[]ST=P<F\1C0
MXQ7*W&0FB35=7HCQ2D&LVQ5,SN5F,@SVP(+%'WK7F?RTA]@S8@\?5HWD9I:I
M8(4<I=_H]:UZ/(,N#Z@5>D(GP&LK\,S4-AB.G8RF2&]B]#V,YU#BG/]3(U45
M%K"FHO409.B1P74&0ZRQB28)UD-N5G0&[O+H YMRR"9JZJ8IGJ,.>%,.]D9/
M)508H'Q3F:B\]E-L.>F.7F=Z_S!YU!Y:YU;*O8=7LN48<?R>Y0]02P,$%
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MO-9.&G_FB^$_7G\!4$L! A0#%     @ I(%14@=!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "D@5%2
MM>5H@.X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " "D@5%2F5R<(Q &  "<)P  $P              @ ',
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( *2!45(\)P"O>P0
M (01   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX
M;6Q02P$"% ,4    " "D@5%2@ZFE ]0!   R!@  #0              @ &^
M#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( *2!45*7BKL<P    !,"   +
M              "  ;T.  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( *2!45*J
MQ"(6,P$  "("   /              "  :8/  !X;"]W;W)K8F]O:RYX;6Q0
M2P$"% ,4    " "D@5%2)!Z;HJT   #X 0  &@              @ $&$0
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "D@5%299!Y
MDAD!  #/ P  $P              @ 'K$0  6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     "0 ) #X"   U$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm216892d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corvuspharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm216892d1_8k.htm">tm216892d1_8k.htm</File>
    <File>crvs-20210212.xsd</File>
    <File>crvs-20210212_lab.xml</File>
    <File>crvs-20210212_pre.xml</File>
    <File>tm216892d1_ex1-1.htm</File>
    <File>tm216892d1_ex5-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm216892d1_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "tm216892d1_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "crvs-20210212_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "crvs-20210212_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "crvs-20210212.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "crvs",
   "nsuri": "http://corvuspharma.com/20210212",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm216892d1_8k.htm",
      "contextRef": "From2021-02-12to2021-02-12",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://corvuspharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm216892d1_8k.htm",
      "contextRef": "From2021-02-12to2021-02-12",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r9",
      "r11",
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://corvuspharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r10": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r11": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r12": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r13": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r14": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r15": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r16": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001104659-21-024824-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-21-024824-xbrl.zip
M4$L#!!0    ( *2!45+&Q@OP1 ,  )P,   1    8W)V<RTR,#(Q,#(Q,BYX
M<V2U5MERVC 4?6YG^@^J7S/"& 9:""23)DW+E"P#29KTI2-D 6IDR95DEGY]
M)2^LAF%I&1[DJW..[I7.E=TXGP0,C(A45/"FXQ6*#B <"Y_R0=-Y[,*+[F6K
MY8#SLW=O@?DUWD,(KBEA?AU<"0Q;O"].P2T*2!U\(9Q(I(4\!4^(138BKBDC
M$ER*(&1$$S.1K%0'E4(5 0AWD'TBW!?RL=.:R0ZU#NNN.QZ/"UR,T%C(5U7
M(MA-KZN1CM1,K#@IIK_=Z#=4X1GY!%U4QA\F'?H\(/QCU$;E'_@[JGZEO3O_
MSX_.2??E=:*#3^5>CW][F+ZPTM/]KU;W<V5ZVRK=="ZNDR4;"@])@( Y"JZ:
MSD)YXW)!R(%;*A8]]_FFW8UQ3@*L3QCEKWEPKU:KN?%L!EU#3GJ29=)EUT[W
MD"(S93-+M^ I5QIQO(3W]8RP"*ZXR>02E.9"JPF49E"?K. 4P86!&+EFPN!+
M15CT8-G+X)&" X3"&:6/5"^63B=R*$KJ=;@)YD.AGH9$Y1*2J1P:EJ,Y PLY
MBE0X1#) UJ\6[YE_R?0<(P'A^EK(X(KT4<1,8K\CQ&B?$M\!&LD!T=: *D28
M[*"8.1EQ+HSA3<^E$1L+0VH<;0)O&O;HZU(P\F J '9@.FVSO@6XE\)<& Z@
M?M-)AE;)Z,9:/NE33N,%T[[R +1=%-D"S3"F--Q5\()$I(A_Q\_B<2B),KRX
M@K8)I,04LH&$$<,1VX\S3R67D@:RG9KO7=8['=('<<_5K1>:CJ+VSG/2V%"2
M?M.Q;H#9$?TTI16,2S*(E=[2<_'.K^Y&NG F@21>4UF[$XR("(G4U!AVH?&3
MU*FV]/N%98!=1SG _1<E,]3;MV1#(>P_UMJV^HM%IDWBSKLD?5[MI(8I5T@-
M^%I;;KLQD[N^+7 LM85BGV#&@S8$O9*Y6@H3Y<\SW2>)^0[LET3&.R")K?=V
M7A9J$\D.X)R]:P);WP(;MB%>/Y?H$J95%CDRF_57QN'IQ%H'Y+-TX+Z6KA5R
MN>"0F^M:4KR;51:9MPG1>J5FO>)5CTSFL$0.SF+)?%A$7,OI_JY=)&8/Q_AE
M]:-D)ZMDI,0F]C/EN P.M>QZ'IO]VG 323/\"U!+ P04    " "D@5%2E58)
MK/X*  #@AP  %0   &-R=G,M,C R,3 R,3)?;&%B+GAM;,V=76_CN!6&[POT
M/[#>FQ88QW&"+I#LS"XRGF1A;#9)8\]LVT6QH"7&$4*3 24G]K\O*8FR1/%(
M2HJ2S$5&([Z'>BD^(:D/4A]_VFTH>B$B33C[-)H>'8\081&/$[;^-/JZ&%\L
M9O/Y"*499C&FG)%/(\9'/_WXYS\A^?/Q+^,QNDH(C<_1%QZ-Y^R!_X!N\(:<
MHY\)(P)G7/R OF&Z57OX54*)0#.^>:8D(S*A./ Y^OO1]QB-QP.R_498S,77
M^WF5[6.6/9]/)J^OKT>,O^!7+I[2HXAOAN6WR'"V3:O,CG?'Y4\1_I$F[.E<
M_5KAE"!YMEAZODN33Z/:85]/C[A83TZ.CZ>3?_YZO8@>R0:/$Z;.6D1&.DKE
M8HN;GIV=3?)4+6TI=RM!]3%.)]I.E;-,33KT-2=I<I[F]JYYA+.\TGL/@T"%
M^M]8R\9JUWAZ,CZ='NW2>*1/?GX&!:?DGCR@O)CGV?Y9@I0FBH-1N>]1D >[
M&2K$1,5/&%GCC,3J0&?J0-/OU8&^*W=?XQ6A(Z24$@^P7&>-O,J@B6NS=T0D
M/+YD[W-M1GNR+_]V1/8_%* >[[P(2YYA^B[S]4CGMF_(^\[X(<[]F9:M/'G?
MF:Y%_E]L9VW+;SZ]]O-*U<YKN=6P2':9[+](K$VJ+#I:X/P(><=0YEWESJ-&
MOE2UYERTRY[*?/,\4Q(=K?G+)":)S/OD6&V,U<;X>%JVV-_)77_,N!P-7*S2
M3. HT_GEA?DTLJ1/3&-*>2&T.RRBGB*6BDG$90?UG(UI<3*+\ ?!-];#EF7G
MEL0_Z*J*+TZ./ 1@M"$3).5;$9$WU4W=+7262D<;*A5J6$78^.MB]&.N0;]K
MU7\^3@ZY.*MN.1S:;@C+EC)?2SF:R:XJVV9*UW4]+8BJMA@R:UI+D-)XJ>8+
M>?A86;BB>&TIA)'NJJ*MMG1--Q*#J&J;([.N*PU2(K^5_86DD4B>U3"_JS0-
MF?.JMYAL$5#3A 5"VQC,0TWKM:F_)^M$=3G*B+KZ)6IG1\,&Z%UW!IVVS=[!
M*@X"G2$.P?ZC'H2J**\T73"VQ?2>/'/1!5%3YIH=FTD3F;HF*%(LQD! "BTJ
MQ%ZY^,=67ML30?>]:+24KND K)J &+*@&+%[ S&IY"&0LA28I8EJTGI1:4N=
M7Y( 9EN7)X8N*%H <_!E2Z4/@9?%(Z%4/4/ K+]QL8E=,P,;-JEI*X/B!K0'
MDI-'H#(D-'@N7]0(7@ZB!A:YIO>)4,MV%T65.%B03(<#6<K#D(KSRE/M048/
M22VE:X8 JR8]ABPH;NS>0&(*.<KUH:!RR>)!H%0Z/Y@8-NV0E*( $6DZZP-$
MJOWC<96D$::%HRNY+^THI$7K&A/0KHE*2Q@4+I [$)DB0).3AP2 S;\(%L.@
MJ2G](-.R:@>FD@6(B^FM#Q:E]XC*;"M$PSO<!\%29P]Z>\Q6SWP!71"X])AK
M/0DNY U<O/9)ERQ+LKUZ6^]FNUD182EB6^**$,B<)L-,#X((P)1)0B%#2H<*
MH<?ZUT\;6*9>E00+9<K<<F WV62AJ0F(!ZLQ@(F#-G]SU2,7,]E6"4SG+":[
M7\@>+%U+YY8,P&83#4,4$!MV9P <I1CE:B3E'O&X$\D&B_TBB7HZC[;0+2"0
MT28AIBH@1 !K ".E&BWF,_]]RQ+OYK&$-GE(BO?0>U@!]6Z1Z;'=) <0!P10
MMT. (QF$FE'^<9JSB(MG7GN=8L:WLDG<SW@,CUQZHMRB-:@(3< Z0P+";(A/
M +9&Z(?BG1?$U1RB/ .D<O#(W44<R].5EO]<)XQ,P;-@U;IEK,-NDRR+,"">
M8'< 1:7R@]Y *@;=LK#0.7E#@4_\HW,R%)V3H-$Y>0\ZRU<>%#JG;RCPJ7]T
M3H>B<QHT.J?O0D=6?P#MSDQNWHHE?[6]&@XJO8#3MFK%YB +#YJ6MSYD5( :
MYZ@0_[#DPZY;<2?X2\(B>$ -R;U@ YBVLF-HPP/(;K"/HFJXK./\HU0.W'O_
M8+3,3XO3-&EO;@I->*@TC?4V-(7:/QAW/,TP_7?RW'G);A=[@<1JV(I*0QD>
M,#9[?=@4,4@&^;L$+]%5#T:L$]R,='=3E2VV#E.5:XE!H&!SU)ZJ7-QM*41^
M*EOQ*@@&6H=FLK.JMIBJ:KJ6%D9%MPVUZCG_&Y<:?W_4:ET:>O?(&?SJ05OB
MJKXA<[K.S?0@ZATP9=9]+D.YSNO]?+5"1FIOT&MISGI\TT[5P>N$(.K8=-/J
MOG6ZESK]3229//Z,;S9;5CXSLKVI".A<U76G35WO5E$0#'0Y,WDHM:@I]@+'
M@M,D2K*$K7^5%ZLBP;:RV42NL( -:B;:BB"  &V9-!R$2"N]H' GB *2R.K(
MIRFJI9+$[<.#=130)7:%1K]AC0BL# *57GLF,C)@'-4B4!&"\I@0X)FGZ9:(
M-R%D"?$$$F@>P*FE#Q$JR&0O6D6@?\(6)-K*?G,_/5DMDXS:+D/;$F>]%&"N
MZJ.,]" ( 4R91.1IB#^@Z<E?5W]#.LH+!#=\*;!:'G>QWZPX!=;3LJI<H=!A
M4=-@D00!!.S+9.*&HU**"JV_];8:EBV%,M)=86"UI0%H) 91]39'K8:@4>->
M.X'+7?0HK1%@:H1=YKHSL)DT.X2Z)@@0.HRU+EQ**=):?U,C#EW9NG]PL/8V
M.%CW# [6(0X.UD,'!VO/@P-]\&*A$]E2W:YHLL;  HR=:M=H=%@V*;%(@P(&
M]@>V'U4(.L3X6;LS7\!-?:! ;'(75W+#4E9 YVSUSBZ;U?*=-E$0I'0Y:RW@
M62RI5Q,CI?9#QS9.,A(7EJX2AEF48%HM!&F[I]X?XHR9@>8K?'KT89 TS&0+
MJB),K]=8!1X6]?1S,[YXS>,W0NDOC+^R!<$I9R0N[L#8GCMUZ]V^E]-CN_EJ
M#B . JHA#H$7=%30^$E%(1U6WC_SR-,W3K<LPR*?_RYLK12@<\L/8+/)C2$*
MB!>[,X"32HP*M<_IY,7J%]40K/@B$UA,2.YX<GFG:6..N54;$#F=!J$9Y^6:
M)8>1<Q'E=1)H1M27-)(7\@5GN'0(EAJ2NY[VV67:G.]ITP8$4J=!<(9G%:,6
MO,&:+,\+WXB9'(BM><>;ZH;*_?(W+8OM%7 J24"0V'QUK(,CD-9Z)&*QP91^
MWJ8)(RG<-1DJMT18+3:):$@"(L+F"R BER*M]4C$Y8:(M>SV?A;\-7LL5Z4%
M2PBHW1+2:;E)BE4:$#%=_@!R= @J8O1"PCX1VAT65B_6DX3+:Y$ZA@<T:Y#3
MTH6$#62NQ0PED;H_<\,SM.3H:TI0]DC09?GYOOJ*^$4^?K_!$D5J@D8Q<F<Q
M%C:0NL3.O\<"&FY]E:6E# *G7GOP%UJJ"*1#O+!S*WD6]2N^W,H\(QMPWD5_
MB"N.AIK7-/7I@V!JH$F3K#RL>1F>!R(5Z7]EIOI2__  L"%R/&ZV&#2&S35%
M$*2 MJ!!<_W+"3Y7!MRN:!)=48[ANS(-C>/U -OVC*4 #X* .&B[@A8 S(4H
M5WJDX#-F3V+[G$7[.\$C0M0;76G5?O7=M1L8[9:<-Q6IR=2@T(!H>XM?@,-#
M%JB6QX=:'^;_%J!Z<5VM5<>CI\4CEJ?Q=INEJF>5]N#[Z)U!CA]0#"B \9BB
M(R(@  ?8A!Y9Y)$H#_V BF!4B_9Z#9<>5CHD\>?]/7D@0LV 6))=]ED>[JGC
M*F1 K.LKO,'%,2_X>@.#0/&M;J'+P135,T K]29:F07Z766"\EQLWX:O[[J6
M6W*WWB5_K7!*Y)[_ E!+ P04    " "D@5%28Y]+9EH'   ]60  %0   &-R
M=G,M,C R,3 R,3)?<')E+GAM;,V<VW+;-A"&[SO3=V"5:QW=I+5B-V,K5D83
M)W8M)6E[DX%(2,(8!#0 J,/;%R E10<"7-UD[<G8"KD ]O\6 KD$P*MWJY1'
M"ZHTD^*ZUFZT:A$5L4R8F%[7O@SK-\/>8%"+M"$B(5P*>ET3LO;NKU]_B>S/
MU6_U>M1GE"?=Z+V,ZP,QD6^CSR2EW>@#%501(]7;Z"OAF3LB^XQ3%?5D.N?4
M4'NB:+@;O6Z\(5&]#JCV*Q6)5%^>!KMJ9\;,N\WF<KEL"+D@2ZF>=2.6*:R^
MH2$FT[O*6JO6YJ<H?L69>.ZZ7V.B:61I"=U=:79=VVMV>=&0:MKLM%KMYC^?
M[H?QC*:DSH2C%M/:MI2KI:Q<^_+RLIF?W9J>6*[&BF_;N&ANW=G5;,^R@/V>
M)YIU=>[>O8R)R8->V4SDM7#_JV_-ZNY0O=VI7[0;*YW4MO!S@DIR^D0GD?MK
M@[=K-99JD>GYC*B4N* UG4&S)VV7M-[F16>*3JYKL5IHVT*G;?]U7/VO#HS,
M>FZ[IF:N9]6BYD';<T4U%2:7>V\/'!2A*V-[%$VV%;GVS_'.,.,*;#I-.ZJ[
M'I:EMCW[L;#<.+-UA\OXP /N(B&/Y#H'M/4@YZUIW)C*13.AS'+OM-P'QZ)5
M;[4WM%_90]_SYF[&VB@2FVU]G(PISUOY;FV.3)H_S;<ME9&MM]RU0XMCS_:#
M>*/B2*J$*LM]6Q=1\4'H3COKQJ(Y)\I65(]GC.^B/E$R]3':\) >1_=QV29^
M)M,;ZT7B/.ES,BV'>F0"I-K&P%JJ!I?K>ZICQ>:.3@7> TL@Y0XJY1)M*+"W
MWZ8G.F7.:^>0NRA3=S \4GB* /%?8(X=0;6H<;@1(B/\B<ZEJL!_: FD_CLF
M]3)MJ+#_SH@R5/$UA/>),1#Y:TSD'H6HU$>*",T<)0CV4VL@]S>H-R<>C:C@
MAS/*N4O_B #U^#)[(/P_,.'[=;X8_'<+=P]@+SSP".P5 0;ASY<2A!.UJ'%X
MI(K)Q%[V%2 ")\9 ]I>8[#T*7P#U.Y% F>],P5D3/O(C>:C ^TS'A!=^]>TQ
M'89>8@X%CY*O5LI\ ?#_I42!T>\90\&CI+ 5$E&P]S*E#EP*CC-^:RAXE.2U
M2B0*^3MAF%F[F87/63K^\6#VD/BI%90T2L+J$X5(>/O$0A@W<1*B?&P))8V2
MIX;$(=+N656*\(%(Z.HC78=PGYA">:/DIT%YB, ?%4N)6@]97#V,G-I"D:-D
MI6&!B,Q'9#5(K#8V8<5D9#5Z;Q%H!%!24I!<Q$ ,1"S57.X]CN[)S'Y#USV9
M!(?ZBH+0H*#DJF=(1PS-39)8:'KSYYX)V@X%I-0</!^%%X: S!<%OW,>_ X<
M/DH.6RGS1<&_. _^!1P^2AY;*1,??L]^?% CN?3,?WN-H>!1\M@*B?C8\^O0
M@WI4<L&*=5M5[$]*0 . F-Z&Q>)'87,C .GY6TLH=<14MUP</NU'J0WA_[%Y
MU3UGN3V4/&+2&Q**\]"RZ /NX8=O@=.1"90R2IY;*@<'K(NVHL3?E0\MH%A1
MDM<R,2A4[Z6;9YE)$7S2>VH%I8N2A?I$X0S(;C&T]@X&>Z?!:^Q0AMMC&2@P
MOREFK!\]F::9V#SQ\<S#>4RAD%%2QZ \%.!#R5G,#!/33_:.4C'"RVF7V4%1
MHR2*?F$HG!\5=5&G]F8]7VGF]D^HA\G$-R*'[*'<4?+$:J$O@?] ZXRJ<Z-0
M4@H:"Y24$2H:9^2A<6:'PW6[,QZY_4"><>?$"DH<)5WTB4(A_%F.%'&[$H?K
M="RY?\-+J2&4,TIR&)"&@OK FW+(1R90O"A98:D<U%'B;A7/B)A2_SJ*<DLH
M9I0L,20.>4R>@L;DZ9EC,DJVZ!.%2KA8X6Z_8P]CSJ;$OULN6 "\?PB3>T J
MSD[%?$.3V\^NTMR;OOU0#M]C"L6.LR4T) \'>)8P0Y/"L3X31,0V'=OMX//D
M]]6EH&' V3,*%(TXB?"-<OY1R*484J*EH$F1((3F$;Q%H+% G+NLD(L8B*^2
M9Y:5RA>O*L_WP6,*!8\X9^F1A[E2M%B4O;LR%2\T"7'WE8#B1YR\#(M%74%G
MJ/.<+>A[8LC&SU 4?"6@44"<R R+1=X%H'KVLC25X7G[(T,H<\3ENZ72$%$/
M4\+Y;::9H#HXVAP90E$CKM,ME8:(^BZE:FH'NP]*+LULLZ,UA-Q3 (H><35N
M4"IF"%8_]M,7._V"_$NLP>]J0(3O%8G[0I(X=@L[BJN]2(CRL _90^FC;B3U
M"T7A_V!F5.W?:>4N#6S.%UI^45T*&@N45!<J&O/*N_=>@^"%]\ .2ATQJ2T3
MAKDC+!MS%O>Y),'[^ ,S*&7$#+9$%B+D6R*>538W\?I1R9A2-U6C=]\_0!H%
MK  :&,3<]BP4F \<9)JZK5(R?A[.K'3]D)G\_;#6R^!CAV Y:( P-ZT"A*/>
M*>D?F]EH<KM^HA.JW(*)$5V96]O<<_C&"5 <&B74MR^!,90$ZZIYHNO>'G!O
M B[.N%_N;;?VR/]02P,$%     @ I(%14D<$I&;;%0  O'4  !$   !T;3(Q
M-C@Y,F0Q7SAK+FAT;>T];5?BNM;?7<O_D,N]<QY=1Z#E1125NQ!QAO$%#Z#.
MS!=7V@:HEK:VJ8"__ME)6BBT5428\9P[<^:,T"1[[^SL]R3U\+^C@8&>B./J
MEGF4DC-2"A%3M33=[!VE/-I-[Z7^6]G<..Q3Z =]3?<HU:?4+F>SP^$P,\QG
M+*>7E??W][,CUB<E.I5'L?URDB1GOUV<M]4^&>"T;KH4FRJ9##)T\R$9/FN=
M=%4<0Y_IRIX$2/+9"&AHU:8#PIUWLZ)QIBN-[5H476G057>M0DXNO42'Z#$9
M,$KJ*S.:88;DVW'K?-J=QO>?=LU2!YMNUW(&F,(:,DC%M)1+YW9#0-(N46<
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M\_G>L+]?:O>[YR=>+SLL_"EWZ-=:[^A(L.3_ 5!+ P04    " "D@5%2.#[
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M%>,HB\OMMU_2>&D\G/W=W7U=4N1_RZ__$B.9_\-SK"39:X]1G3C_*:JGQB2
M2Y<L4J0+'7N(8?UL&J%.Q9\NT*L%ZQ_^9<-H=+WQ"6#VX:(]DZ.T08N1;USX
M6]E":V1>IR=4<P""!QY?Y&=L.>(2W[$/8HI%#B>3O,YHS6_/X"U43_D\AW6:
M9)>P+:P'T\)OHG(:_85" RNM?H^*SW&%19>:N-:])$IIXMZQMN$_XS'V.9<B
M]CU%U%W>0HZELQ5Z@BS.$W&ZH!FJT:H@F<_C:0+_2I?(S!AUR?DA^.IF(0RJ
M!":O5EUY<8GJ%;6(3LT9="G.#KVYF3KL\]Z'@SR#G3N%"+>U1A<<Z4YD(#,:
M_JA(/]+E4>KSLH8K3CO:PB/H-^&5L3T<*(6[?V\TIJ)+L>Y5FOCN1LF-^@CN
M,E!^&TBZ_4>$]8/# 9*VSD"X-C*]RO+.T9+& AI0-."C4Z&L_0D?TB*'/U0)
M?,\ZY5Q74T6?8TS[XIU+(KRF\),XH6B.Q%^&@_NCJ0Z]X+LH,[_WX."YC9=V
M:92[DY63_8./9CAH'W&PP0FO^Y45C=$*)F!1P0D#O-]8I4GU%;OW&\6+/_:I
M?<J DTL7D1P.K!,14LVHI]#DC-' ,.>6E$9QP:/Q!$!4XM^_ RJW?WYM1<1C
M*B)&&TX$#_(H:$Z_Y.$]AX%0\4B9\"C9"D:'6\%AY;R\%0D;TJZ@1I>@-B?1
M7!4%AL'H^9;I '!%DQ$H\U91K,W9:$T^P;4O\2J1C#6)2XI4CPX\B3DZ/XU)
MIH(%"[^OME5IHGU9Z!?;%C'\%PG;MIX&$W]T9!?O.^M]YA/*YM$+2EWC)D&U
M<'8VP.3LRAI0,#]P"3';TU2G*1]1G1#\<XY""=6+F$7V!A3J_!1!V-OLU1M<
ML)JPK6#?B?\0PX>D(MC\11WK\N\97$B[E%G$JBJ?)VRFX??PAR "O>\T0HWT
MO:DM;X8G9#$X.25VZ,$WYJ QN=[?O+>TWZ7>D*1,XP@M*.X3&"7)%E\WY%I4
MIQA?F1+-&PR(&YAQ5;V0BI(W.HS6$\LDZTK>=V2/.&B=\'#0>N)5'&>P_C3Q
M-</!51UA<+$3A!=O>(048D[)@Y3M39)B4L_1\YW8*O_STV1"EN\R.(>?P0.G
M0%__]*D$>3A8%/!FLJ>QEX3TQC2/)0X*-O72[HO7P1R7BSD-EC:XPK1C\C)L
M6?XX*K$T>H&Z732^JN,;#F9UD27E*9-$!<=1 .'SL7 >O(L9$1P^5DTK)F8V
M(:F)@J\N8T6?2C(W1 HP)?.IZX>9DB7"G37D?="JO0I#DU6,RTF1C%&FE.9;
M5H0^0NT@Y1]>7\@\CJNRS8EFD=C4@PT@ ?9_7+NVO49C9;/*MOTG ;=_E;_@
M&X1Z3X)_8EL<_/EF"M_:#=P7MQIX-;L=BZ':MJ>OWK[YJ(F[72;_COD%\%=%
M(D.<)\''Y0*^<5A$XV3R)'@#6I8)^"9'LNQ[A7'F5_B7IS_CRY[](+5[WZ![
M;++%G;#@<)XD&#*4!!#%,-C(&P[0RA,+C_LQ2H[:!-&LDEOM:\H>TX7#/4J"
M8#@QXVH%5\- 0:ED@7H517D0#0?C/(O@%=.8OP86G'6A@J8'M??@WNAT:[2_
MM=51V8#ZWRCY[G+!T%N@M*&PA6029ID-I#JR<4QU?;IV][X.=8V^B#72(@H*
MZW&93).(FH2\]D@39W+:3/?#X!)/HS/\F)IYP)HX2R84O$5U/HO3G%\"6FT:
M(_50!17>;XCNI)/K\9\Q1;RQQ/Q/6/4DX?A&-)V#-<^'#+;N-)[@$NA1*.F)
M $:I-$G 1['LV/NJG;'!HI?IKQ V-XZRST6]J"9@V,=58H*&209R\@QD"NV[
M3.8)ACS!@)_$,=N&ZLFGT;2WIQ$XL4D7CLS)@T3->;4RCYJF&;Z+E?9%GW0H
M_3O\+&HJSC+1TC;\9R^2Q_TAF9(K3^46=>BUQ-R4Q)Q)=+_@(JH:C,5WH$E!
MF(N@<WU[KA:97HP<DI&T&"6*;==DSI5E/XK++1824Y0_U-AJ@^#Z=5P#2947
M<"%"<QU28-H,94%G&#@D838-''C)'H.7:&&#3T)+53^"?_9[5(#)]YA^L@OB
MGBWJ1*J"P4/&Z@T4X)UU:;;LB.U;%].4NJ1TN65=$I;UR@1U&Q4_(<& _<JR
MHYZH>__A,N][8?L3#@",VNF^CEJN+G;1^3WG5+((FR9GR12#^U+&L0%[A.#%
ML*QNK9$C,:MWB/P$JT#=YJ] 0IUK8Y9?^?[0G<8%'4EAFCY?TGJ*5%?$JF4#
MGQ'_='5^HU-'P\%7^HU=%RC<I&*'C8+A8-,#A:>2$M?)!')0R9#)3(PAJ9:L
M.3K\UJ#/;04M> -^:]#KMFJ'>H.5$%.7+D2BM[C*\16EJ[S?6ZP@8_$#5,CS
MA80WC!> -\&$/,H54 0=B6!=U22:8)4P(5GD+B;E-\'T*5I1XZZD9Z@BI)>)
MH'FU[%[) GL!NM2&^)FE"5MV;"-XT:&2>@ZH./+KA*/]#O#_E49*+R,RAX->
MF?F$;S)L%:XIJ1!'BC*7;#6+H<NQ$$?_AX.U+-0X!^">W.,>%*K%BA)8*I4F
M6J#9-(\P;1%Z,5I22Y<*TDH*0W,;=TQ82S#T@^W"19T\1'[!^E#M!0.UFS.0
MK?J]&J5[>^7L)H'$@[N8X08QPX.[F.'FC'U=W;TM,V+&9L1*6S8V!L5+S(JM
M\XN,>^BJH1GE;LH. WG3*( Q7$9,P*%)E$U%7I^P2*?D<*QQHKAS"N7F3)0W
M=0/Z$4.T6K,J24GF&B0: :!I1#)!@G%E,XI-_F]6'1X 63/^0FHL TK:?%1H
M,JVA\C#Z<J[:DJ45H59**=@7VO\N+9R/^<2I.L^HKL0#%%MEI0[>"8YG!B2+
M(L$S<*3S<SP\/!ZN7<*36^?7<.EJ@EE!XV2H-"DKF""?3.JB8.+2?^/O@OA,
MC($I_%>:+TS%.0;ORCHE-<3JANR -0MQI"-+\SROT^EJB@47(1C9&A=9FZ[C
MI%M0Q,2SY/7H8DI'>7I4%U5"V8[CG4VL4**#,4,M25:;%,YBN#IW?3C8W'0(
MJ2)%7TQL;L<*YD65^K>4KH3_EV7'C478-,H:]#Y4>ES;SZ0_4,39!NHV8D6@
MF,3[,$$!-P/,Y )CQ/1CPY-AQQFZF$,C</&5^>[A8,V2KRW6P X^5L]^FUB#
M6]A&48^[6,,&1L()!^/Q'#Y@#X-*5F@ 4(XXZ"O'T'>(2.>YCI*;B[\D%!,S
M;'>"+RC-"UP!0AJ=NZ;G2I* !M@W-"6ZY]C026Q25Z=Y@<P[LN]T7=);R*_Y
M>4:6"2+MQ87%? !F0'1A[J^M0:EA)6.'"; B%N)*LYJE0D]L;,+FSDJFS5\U
MV/(DY6!IT]Q[=435[F#I>P#&+6*)4RO-XG_615).DPG'/.!ODA] -C^'E9>G
MR0)O!LA@*OLP=%@:)]<00@PXNR!Q0.4VR+I-0#K^,HF!D\[Q/G#\>18E*=)&
MW-5<[922?.U-T',YY^!O@G49F5DN6IXNY3GX,@LSC.VU49EGX)(O*?\7?\$3
M8/**-B> +JL)HRDVOIA @T&G02)P1G*$W?>92:3:TM:M4!Y'W(D4-)%<0[ 0
M*Y@LBREPU+)Q?_@*8+S%))$3O*Y<7TYL<'Z:IQXT\^]F]8>R>JYCO*%FFV\N
MDTY))GU0Y.("UY=4G.GEXEN6P-6+)9]9,?F>>"%7SMA8015<OYQ:EP%B<41U
MCOW$^AH)-1STBZC@9B34<+!"1 4W(Z'(*%\EHH(5$JKGCC]A2HK%(CEJ9)RZ
MLDN=1(ND0C!U;--SM=F;7@QASG_+D\^ *E.\+^YEV,=4HPA>1,G41-.CLD1W
M8IS&3MW)2A"E$CL&NU9RGKGV1%D/^M5H0Z=RY!P;\,5C4LI/"8R!;%_P^%$
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MO?U[V'/7"+CSP6':S;-A&XXTXS<;Q![MKOE5IHUZ%AX:/3U+Q+!NBIGY@@9
MJ$&8,R*DM[/6#J0KA("H2^RPG]'8DZ6SJSJ-0V/FH/F#T1EZT_>;S=T <$K0
MT5(!.C[$?B*ZVT^&@_=QN<#Q.68NC+#4>]3F9=4N7V9&MF?6=ZAFI!*ID(AB
MHM3&1!&D>F&Z8:.**TLXJ ,/Z89?,R&BKG$*7L3%"^PS=V,U<R(8Z+$&_=!
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M)7\L-9F<@X_ZE"#Y=8X3*,-0617_G;6F=K]D;Y?,G@]U<893R D]2X#^WOM
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M)^_?OJDX%?/Y[*#7RS]GDF?22Z:$F/-GB_TH>BTV4MH3NN8JW^=1+/99_HZ
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MOD\U9=',TX@77Y!L, 1Y:*Y2;;)O##.KA3PM? E9:81H<*FM&B/G)UE^L1'
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M,C$V.#DR9#%?.&LN:'1M4$L! A0#%     @ I(%14C@^P/8T>@  3)H" !0
M             ( !.RP  '1M,C$V.#DR9#%?97@Q+3$N:'1M4$L! A0#%
M  @ I(%14KJ+5Z?0"@  5S<  !0              ( !H:8  '1M,C$V.#DR
B9#%?97@U+3$N:'1M4$L%!@     &  8 B $  *.Q      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
